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Cancer in The Netherlands 
Cancer remains a major health problem. In The Netherlands around 70.000 new cases 
were diagnosed in 2000 and approximately 38.000 patients died from cancer [1]. 
Lung cancer is one of the most deadly types in both males and females. It accounts 
for a significant part of all cancer cases with an incidence rate of 52.4 per 100.000 in 
2002, and can be regarded as a disease of the elderly, as the peak-incidence is found 
at the age of 70-74. Therefore, ageing of the population is expected to result in an 
increase in the incidence of lung cancer. 
 
Radiotherapy 
Radiotherapy is an important modality in the treatment of cancer. It is estimated that 
50% of all cancer patients undergo radiotherapy as part of their treatment. 
Radiotherapy can be applied as a single (local) treatment modality. It can be used 
following surgery to destroy cancer cells that were not removed, or prior to surgery to 
"shrink" a previously inoperable tumor to enable surgical excision. Chemotherapy and 
radiation therapy may also be combined for the effective treatment of cancer. Finally, 
radiotherapy can be used to relieve symptoms of incurable cancer, such as bleeding or 
pain. 
 
External beam radiotherapy 
The current routine for external beam radiotherapy planning and delivery is commonly 
referred to as 3-dimensional conformal radiotherapy (3DCRT). 3DCRT makes use of 
multiple radiation fields that are closely tailored to the shape of the planning target 
volume to deliver a homogeneous dose, while limiting the radiation dose to 
surrounding normal tissues [2-4]. Many steps are involved in the external beam 
radiotherapy process, and the overall accuracy can be affected by errors at each step. 
In many cases immobilization devices are used to establish reproducible patient 
positioning during treatment planning and daily treatments [5]. Next, a computerized 
tomography (CT) scan of the region of interest is performed in the patient’s treatment 
position in order to use the 3D anatomy for treatment planning. The planning CT scan 
is usually acquired during normal free-breathing as patients commonly undergo daily 
irradiation under the same condition. Digitally reconstructed radiographs (DRR) are 
generated from the CT dataset, and can be used as a template for verification of the 
patient’s position during treatment. To define a common point of reference between 
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the actual anatomy and its 3D representation ink marks are made on the patient’s 
skin (tattoos). Furthermore, ink marker lines are placed on the patient’s skin with use 
of the laser alignment system. The CT data is imported into the treatment planning 
software. The radiation oncologist then contours the gross tumor volume (GTV). This 
consists of all clinically macroscopic disease, including that which is visible on imaging 
modalities [6], and (if indicated) the adjacent organs at risk (OAR) on all axial CT 
images.  
 
Several safety margins must be added to the GTV in order to establish adequate 
treatment (Figure 1). These margins account for microscopic tumor extension (clinical 
target volume; CTV) and geometric uncertainties such as patient movement, 
positioning uncertainties, and organ motion (planning target volume; PTV) [5, 7, 8]. 
The International Commission on Radiation Units and Measurements (ICRU) Report 62 
[9] furthermore recommends the use of an internal target volume (ITV) to account for 
variations in size, shape, and position of the CTV (Figure 2). Information about the 
amount and nature of the CTV motion is essential for the determination of the internal 
margin size. 
 
 
 
 
Figure 1. Illustration of different target volumes derived from the GTV 
 
 
 
 
 
 
 
 
 
 
 
GTV 
CTV 
PTV 
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Figure 2. Target definition according to the recommendations in ICRU Report 62 [9] 
 
 
 
 
 
 
 
 
 
 
 
 
 
Based on the PTV and OAR’s, a treatment plan is generated by optimizing the number 
of beams used, the beam angles, beam weights and beam energies. A treatment plan 
is regarded optimal when a homogeneous dose delivery to the target volume is 
possible, without exceeding the maximum tolerance dose of normal structures [6, 9]. 
The patient’s treatment can commence after a suitable treatment plan is approved. 
Electronic portal image devices (EPID’s) are frequently used to verify the accuracy of 
daily patient treatment. EPID’s are generated using the exit radiation dose in order to 
obtain 2-dimensional images of the patient’s anatomy, and accuracy of patient setup 
is determined by comparison with DRR’s.  
 
The ultimate goal is to exactly reproduce the entire setup, i.e. the patient’s positioning 
during CT scanning and the beam geometry that was generated with treatment 
planning, in order to deliver the prescribed dose to the intended anatomy. 
 
Geometric uncertainties in radiotherapy 
In recent years, radiotherapy treatment planning has increasingly used conformal 
techniques, and a high level of geometric accuracy is required to ensure delivery of 
the prescribed dose to the target volume. The most important causes of geometric 
ITV 
PTV 
CTV 
GTV 
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uncertainties in radiotherapy are 1) variations in delineation of target volumes, 2) 
setup errors, and 3) organ motion. Errors arising from these geometric uncertainties 
can be divided into systematic errors, which are repeated during all fractions, and 
random errors, which can vary between treatments fractions. As random errors will 
point in different directions for different fractions, they generally have a smaller 
impact upon the delivered dose than systematic errors. Random errors will cause 
blurring of the dose distribution [10], and lead to a small decrease in the dose at the 
edge of the high-dose region. However, systematic errors result in suboptimal tumor 
doses, because they are repeated during all fractions. 
 
Geometric errors in target volume delineation are systematic errors and can be 
introduced by factors such as suboptimal imaging protocols [11], interobserver 
variation [12, 13] or inter-institution variation [14]. Setup errors both have a random 
and a systematic component, such as limited reproducibility of patient positioning due 
to skin motion with respect to the internal anatomy [15]. Organ and tumor motion is 
also an important source of geometric uncertainty [16, 17] and is the cause of both 
random and systematic errors. Lung tumor mobility has been reported to range from 
0.6-25 mm, with motion of 10 mm or more reported in 28% of patients [18]. 
 
Approaches to address tumor mobility in radiotherapy planning 
There are essentially four approaches to address the problem of tumor mobility in 
radiotherapy planning: 1) Use of an ITV based on 3D tumor mobility that is present 
during quiet respiration; 2) Breath holding-techniques; 3) Respiratory gating; and 4) 
Tumor-tracking. All these approaches have the aim to generate individualized target 
volumes. 
 
All tumor mobility can be used to derive a planning target volume by performing 
multiple CT scans during quiet or forced respiration, and fusing the separate target 
volumes to generate an ITV [19, 20]. Furthermore, recent work has shown that the 
mobility of peripheral lung tumors can be fully characterized with a single ‘slow’ CT 
scan and a 5 mm expansion of the ITV [21]. However, use of the ‘slow’ CT technique 
is only applicable to tumors located in lung tissue because of the high contrast 
between tumor and normal lung tissue, and not for mediastinal structures [22]. 
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A second approach to tumor mobility would be to control the target motion by 
attempting to actively or passively influence respiration-induced movements, which is 
typified by approaches such as deep-inspiration breath-hold (DIBH) [23] or active 
breathing control (ABC) [24]. However, up to 40% of patients with lung cancer cannot 
tolerate breath-holding [23].  
 
A third approach is respiratory gating, where radiation is delivered only during a pre-
defined part of the respiratory cycle in which the tumor exhibits relatively little 
mobility. Clinical experience with gating for liver tumors has shown that reductions in 
treatment margins are possible [25]. 
 
The final approach to tumor motion is the use of tracking and control systems to 
monitor tumor position, and to continuously adapt radiation fields during free 
breathing. Fiducial markers that are implanted in, or adjacent to, hepatic and lung 
lesions have been used for fluoroscopic tracking of the target volume during 
radiotherapy [26]. However, the insertion of markers carries all the risk of an invasive 
procedure and markers are often placed next to instead of in the tumor. The 
placement of at least 3 tumor markers is required to identify rotational movements 
[27], but this is seldom possible. 
 
4-dimensional radiotherapy 
A potential solution for the problem of respiration-induced mobility is 4-dimensional 
radiotherapy, in which respiratory movement is accounted for during imaging, 
planning and treatment execution [28]. This approach requires a respiration-
correlated CT (4DCT) scan in which changes in position and shape of the internal 
anatomy of a patient are quantified as a function of the respiratory cycle. The 
corresponding respiratory phase at the time of image acquisition is digitally ‘stamped’ 
on each CT image. Once the 4DCT scan is performed, 4D software automatically sorts 
the images into individual 3D image sets, each representing the entire patient’s 
anatomy during a single respiratory-phase. This enables tumor and organ movement 
to be visualized, and utilized for determination of individualized margins for treatment 
planning. Such an approach can be combined with breath-holding, gated irradiation 
and can also be used to generate target volumes in which all respiration-induced 
mobility is incorporated. 
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Aims of this thesis  
This thesis describes the early clinical evaluation of 4DCT scanning using a multi-slice 
CT, in order to optimize target definition in non-small cell lung cancer (NSCLC). The 
geometric and dosimetric outcomes of target definition in stage I NSCLC using three 
different CT scanning protocols, including 4DCT, are evaluated in Chapter 2. The use 
of 4DCT scans increases by ten-fold or greater the amount of data that are used for 
generating target volumes. As manual GTV delineation in up to ten 4D datasets 
significantly adds to the clinical workload, the use of post-processing tools was 
evaluated for rapid ITV generation (Chapter 3). 4DCT datasets enable tumor and 
normal organ mobility to be visualized as a function of the breathing cycle, thereby 
enabling respiratory gating to be performed in order to reduce target volumes. 
Chapter 4 describes the benefits of respiratory gating in extracranial stereotactic 
radiotherapy (ESRT) for medically inoperable stage I NSCLC, as well as simple 
approaches to identify patients that are suitable for this type of treatment. 
 
ESRT enables delivery of biological effective doses of up to 180 Gy to stage I lung 
tumors. As target definition has to be optimal during the entire course of ESRT, the 
impact of inter-fractional changes of the target volume is characterized in Chapter 5. 
 
4DCT scans also enable characterization of mobility of the hilus and the mediastinal 
lymph nodes, thereby permitting 4D respiration-gated radiotherapy for locally 
advanced lung cancer. Currently, radiotherapy for stage III NSCLC is characterized by 
large target volumes, as population-based margins are added to the CTV to account 
for organ mobility and patient setup errors during treatment. In Chapter 6 the 
geometric and dosimetric consequences of 4D respiratory gating in stage III NSCLC 
are evaluated in order to establish accurate dose delivery and limit the risk of 
treatment-related toxicity. 
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Abstract 
Purpose: Hypofractionated stereotactic radiotherapy (SRT) for stage I NSCLC requires 
that meticulous attention be paid towards ensuring optimal target definition. Two CT 
scan techniques for defining internal target volumes (ITV) were evaluated. 
Methods and Materials: Ten consecutive patients treated with SRT underwent six 
‘standard’ rapid multislice CT scans to generate an ITV6 CT and one 4DCT scan that 
generated volumetric datasets for 10 phases of the respiratory cycle, all of which were 
used to generate an ITV4DCT. Geometric and dosimetric analyses were performed for 
[a] PTV4DCT, derived from the ITV4DCT with the addition of a 3 mm margin, [b] PTV6 CT, 
derived from the ITV6 CT with the addition of a 3 mm margin, and [c] six PTVs10 mm, 
derived from each separate GTV6 CT, to which a 3D margin of 10 mm was added. 
Results: The ITV4DCT was not significantly different from the ITV6 CT in 8 patients, but 
was considerably larger in 2 patients whose tumors exhibited the greatest mobility. 
On average, the ITV6 CT “missed” 22% of the volume encompassing both ITVs, in 
contrast to a corresponding mean value of only 8.3% for ITV4DCT. Plans based upon 
PTV4DCT resulted in coverage of the PTV6 CT by the 80% isodose in all patients. 
However, plans based on use of PTV6 CT led to a mean PTV4DCT coverage of only 
92.5%, with a minimum of 77.7% and 77.5% for the 2 most mobile tumors. PTVs 
derived from a single MSCT expanded with a margin of 10 mm were on average twice 
the size of PTVs derived using the other methods, but still led to an underdosing in the 
2 most mobile tumors. 
Conclusions: Individualized ITVs can improve target definition for SRT of stage I 
NSCLC, and use of only a single CT scan with a 10 mm margin is inappropriate. A 
single 4D scan generates comparable or larger ITVs than are generated using 6 
unmonitored rapid CT scans, a finding related to the ability to account for all 
respiration-correlated mobility. 
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Introduction 
The local control rates after curative radiotherapy in patients with medically 
inoperable stage I non-small cell lung cancer (NSCLC) have been disappointing [1]. 
Even the use of 3-dimensional (3D) conformal radiotherapy to doses of up to 70 Gy 
has failed to improve upon these results, with local failure rates still as high as 40-
60% at 3 years [2]. Approaches for dose-escalation using conventional, hyper- and 
hypofractionated schemes have been investigated as a means of improving local 
control. Recent studies have reported unacceptable toxicity with conventionally 
fractionated doses exceeding 90 Gy [3, 4]. In contrast, several phase I/II studies 
using hypofractionated stereotactic radiotherapy (SRT) for stage I NSCLC have shown 
that high local control rates of 90% or more can be obtained with only limited toxicity, 
although the follow-up is relatively short in some series [5-12]. 
The application of high-dose radiotherapy, however, requires meticulous attention 
towards ensuring an optimal target definition. Recent studies have shown that 
individualized (i.e. ‘patient-based’) margins, as opposed to standard ‘population-
based’ margins, are required for radiotherapy of lung tumors [13-15]. Approaches 
used for determining individualized margins include ‘slow’ CT scans [16, 17], and the 
co-registration of expiratory and inspiratory target volumes [13, 18-20]. 
 
When the extracranial SRT program for stage I NSCLC commenced at our center in 
April 2003, the option of performing ‘slow’ CT scans on the CT scanner was not 
available. Therefore, target definition was based on the use of 6 rapid unmonitored 
spiral multi-slice CT (MSCT) scans in order to generate an internal target volume 
(ITV), a lengthy approach that requires laborious co-registration. Recently, a 16-slice 
CT scanner became available, and it allowed for 4-dimensional (4D) or respiration-
correlated CT scans to be performed. 4DCT scans generate spatial and temporal 
information on mobility in a single investigation and represent a major breakthrough 
in imaging for radiotherapy planning [21, 22]. In this technique described as 
‘retrospective gating’, the respiratory waveform is synchronously recorded during CT 
acquisition, and multiple CT slices are acquired at each table position for at least the 
duration of one full respiratory cycle [23]. This yields CT datasets for 10 phases of the 
respiratory cycle. 
 
We evaluated the use of 4DCT scans as the sole technique for generating ITVs for 
peripheral lung tumors and compared this with target volumes generated using our 
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routine 6-scan approach. The dosimetric consequences of treatment planning using 
both methods of target definition were evaluated, and compared to the use of 
‘standard’ planning target volumes (PTVs). 
 
Materials and Methods 
Ten consecutive patients with peripheral stage I NSCLC, in whom both CT scanning 
techniques were performed for planning hypofractionated SRT, were included in this 
analysis. All patients underwent staging using an FDG-PET scan and only involved-
field radiotherapy was performed. Tumor characteristics are summarized in Table 1. 
Five patients had lesions located in the lower lobes. 
 
 
Table 1. Tumor characteristics in 10 patients. 
 
 
 
 
 
 
 
 
 
 
 
Multiple unmonitored CT scan technique 
Our routine technique for generating ITVs for SRT of stage I NSCLC involves the 
performance of 1 full-length rapid conventional spiral CT scan and 5 short scans 
limited to the tumor region. Patients were positioned supine, with the arms positioned 
above the head on an adjustable arm support. 
The gross tumor volumes (GTVs) were contoured on all scans, and the contours were 
projected onto the full-length scan.  The multiple CT scans are currently performed on 
a 16-slice GE Lightspeed with a slice thickness of 2.5 mm and an index of 2.5 
(contiguous reconstruction). No intravenous contrast is used for these CT scans, and 
the whole procedure generally takes about 20 minutes. 
 
Patient Stage Tumor location 
A T1N0M0 Left lower lobe, central 
B T1N0M0 Left upper lobe, adjacent to mediastinum 
C T1N0M0 Right upper lobe, subpleural 
D T1N0M0 Right upper lobe, subpleural 
E T1N0M0 Left upper lobe, subpleural 
F T1N0M0 Right upper lobe, central 
G T1N0M0 Left lower lobe, central 
H T1N0M0 Right lower lobe, central 
I T1N0M0 Right lower lobe, central 
J T2N0M0 Left lower lobe, subpleural 
Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer 
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4DCT scanning technique 
The 6-scan procedure was followed by a single 4DCT scan using the Varian Real-Time 
Position Management (RPM) respiratory gating hardware for recording the breathing 
pattern (Varian Medical Systems, Palo Alto, CA) and 4D imaging software (Advantage 
4D, GE Medical Systems, Waukesha, WI). The patient’s position was maintained 
between the multiple scans and the 4DCT scan, in order to minimize patient 
movement. Briefly, the respiratory signals from the RPM were recorded using infrared-
reflecting markers on the patient's thorax during uncoached free breathing, as 
previously described [22, 24]. The markers are illuminated by infrared-emitting diodes 
surrounding a camera, and the motion of these markers was captured by the camera 
at a frequency of 25 frames per second. A respiratory signal is recorded in 
synchronization with the X-ray ‘ON’ signal from the CT scanner. The LightSpeed MSCT 
scan can simultaneously generate 16 slices of 1.25 mm (16 x 1.25), 8 slices of 2.5 
mm (8 x 2.5), or 4 slices of 5 mm (4 x 5) for a 2 cm total coverage per gantry 
rotation. Our current scanning protocol for lung tumors uses 8 slices of 2.5 mm (8 x 
2.5), obtained during quiet respiration. The 4DCT scanning procedure of the thorax 
takes about 90 seconds. The time resolution for a single image acquisition was 1/10th 
of the full respiratory cycle period. The 4D data sets were sorted out for ten phase 
bins within the respiratory cycle using an Advantage 4DCT application running on an 
Advantage Workstation 4.1 (General Electric Company, Waukesha, WI). The 
registration is made based on the nearest neighbor criterion, where at each slice 
location the image is selected so that its phase is closest to each phase bin (Figure 1). 
The volumetric datasets that represented 10 phases of respiration (bins) were used 
for further analysis. 
 
Contouring of target volumes 
All sixteen CT data sets, i.e. six MSCT scans and ten bins from the 4D scan, were 
imported into the BrainLab stereotactic radiotherapy planning system (Brainscan ver. 
5.2, BrainLab AG, Heimstetten, Germany) and co-registered using the automated 
matching software of this planning system. Match results were checked visually by 
contouring one CT slice of a spinal vertebra adjacent to the tumor, which was then 
automatically projected onto each CT data set after the registration procedure. GTVs 
were contoured in each of the 16 CT data sets using a standardized lung window level 
setting (W=-500, L=1000) by the same clinician in order to minimize contouring 
variations. 
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Figure 1. Overview of respiratory phase “bin” generation from 4DCT-data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Volumetric analysis 
A total of sixteen GTVs were obtained per patient, i.e. six from the multislice CT scans 
(GTV6 CT), and ten from the bins of the 4DCT scan (GTV4DCT). All contours were 
automatically projected onto the first ‘bin’ of the 4DCT set, which was used for further 
analysis. The ITVs (ITV6 CT and ITV4DCT) were defined as the encompassing volumes of 
the GTV6 CT and the GTV4DCT, respectively. The agreement between both ITVs was 
investigated by determining the ratio of the common overlapping volume (COM), and 
the encompassing volume of both ITVs (SUM). The spatial positions of the ITV4DCT and 
ITV6 CT in X (medio-lateral), Y (anterior-posterior), and Z (cranio-caudal) axes were 
compared for all patients using the coordinate system of the Brainscan planning 
system. 
 
Mid-exhale “End-exhale” “Mid-inhale” End-inhale 
Full respiratory cycle End-inspiration 
CT Image Sorting Program 
End-expiration 
4 sec 
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Dosimetric analysis 
Three PTVs were constructed for dosimetric analyses, namely [a] PTV4DCT, which was 
derived from the ITV4DCT with the addition of a 3D margin of 3 mm, [b] PTV6 CT, which 
was derived from the ITV6 CT with the addition of a 3D margin of 3 mm, and [c] six 
PTVs10 mm, which were derived from each separate GTV6 CT with the addition of a 3D 
margin of 10 mm. An ITV-PTV margin of 3 mm is clinically used for extracranial 
stereotactic radiotherapy at the VU University medical center, in order to account for 
residual errors in patient positioning using the online correction protocol from the 
Novalis ExacTrac system (BrainLab AG, Heimstetten, Germany). The GTV-PTV margin 
of 10 mm added to each GTV6 CT was assumed to be sufficient for incorporating both 
target mobility and patient positioning errors for this technique. The optimal beam 
arrangement required for the 6-scan ITV (ITV6 CT) was considered as the standard 
treatment plan of all patients, and coverage of the different PTVs by the 80%, 70%, 
60% and 50% isodoses was determined when the standard SRT plan was applied to 
the PTV4DCT, PTV6 CT and PTVs10 mm, respectively. The dosimetric consequences of 
treatment planning using the 3 different PTVs were analyzed in the Brainscan planning 
system using dose volume histograms. 
 
 
Results 
Volumetric analysis 
The mean GTVs derived using both CT techniques were comparable, ranging from 1.1 
to 36.8 cc for multiple MSCT scans, and 1.5 to 38.8 cc for 4DCT scans (Table 2).  
 
In order to estimate the extent of tumor mobility, the ratio between the mean GTV6 CT 
and ITV6 CT was calculated for each patient. For completely immobile tumors, this ratio 
will be 1. The mean ratio GTV6 CT/ITV6 CT was 0.58 ± 0.17, and was particularly low in 
patients A (0.36) and G (0.26), both of whom had tumors of the lower lobe. 
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Table 2. Target volumes obtained using multiple MSCT and 4DCT scans in  
10 patients. 
 
 
The volume of the ITV4DCT was not different from the ITV6 CT, except in patients A and 
G, where the ITV4DCT was considerably larger (Table 2, Figure 2). The ratio between 
the ITV6 CT and the ITV4DCT ranged from 0.49 to 1.04 (Table 3). The agreement 
between both scanning methods, as assessed by the ratio between the overlapping 
and encompassing volume (COM/SUM) of both ITVs was 0.71 (range 0.47 to 0.83). 
This was caused by a substantially larger surplus (i.e. the volume of each ITV outside 
the COM volume) of the ITV4DCT in all but one patient. The ITV6 CT “missed” on average 
22% of the encompassing volume of both ITVs, in contrast to only a mean 8.3% for 
the ITV4DCT (Table 4).  
 
 
Table 3. Comparison of ITV6 CT and ITV4DCT. 
Patient 
COM ITVs 
(cc) 
SUM ITVs 
(cc) 
COM/SUM ITV6 CT/ ITV4DCT 
A 2.8 4.6 0.62 0.65 
B 10.3 15.1 0.68 0.91 
C 11.2 15.2 0.74 0.85 
D 30.5 38.7 0.79 0.89 
E 7.3 9.3 0.79 0.91 
F 2.9 4.2 0.69 0.86 
G 7.8 16.5 0.47 0.49 
H 5.6 8.1 0.69 1.00 
I 23.8 28.8 0.83 0.96 
J 47.1 58.9 0.80 1.04 
Mean - - 0.71 0.86 
SD - - 0.11 0.17 
      “COM” refers to the overlapping volume between both ITV6 CT and ITV4DCT. 
      “SUM” refers to the encompassing volume of both ITVs. 
 
Patient 
Mean GTV6 CT 
(cc) 
Mean GTV4DCT 
(cc) 
ITV6 CT 
(cc) 
ITV4DCT 
(cc) 
PTV6 CT 
(cc) 
PTV4DCT 
(cc) 
Mean PTV10mm 
(cc) 
A 1.1 1.5 2.9 4.5 7.0 10.7 19.2 
B 6.9 7.5 12.2 13.3 23.8 25.8 58.4 
C 9.1 10.5 12.0 14.0 23.3 26.6 61.6 
D 22.7 23.2 32.3 36.2 53.7 58.8 107.8 
E 5.6 6.2 7.9 8.7 16.5 17.4 46.1 
F 2.2 2.5 3.2 3.7 7.9 9.1 27.8 
G 2.1 3.7 7.9 16.1 18.3 31.2 28.5 
H 3.2 3.9 6.9 6.9 14.2 14.5 32.0 
I 16.2 17.3 25.6 26.6 42.1 44.4 79.6 
J 36.8 38.8 53.0 51.1 81.1 79.7 149.5 
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Table 4. The surplus of ITV6 CT and ITV4DCT (SUMITVs – ITV4DCT and ITV6 CT, 
respectively) 
 
 
The position of the center of mass of the ITV4DCT and the ITV6 CT was comparable, with 
a mean difference between both ITVs of 0.6 mm, 1.3 mm, and 0.8 mm in the X, Y, 
and Z-direction, respectively (Table 5), with a mean 3D displacement vector of 1.7 ± 
0.6 mm. 
 
 
 
Table 5. Positional shift (mm) between the centre of mass of ITV6 CT and  ITV4DCT 
 
 
Patient 
Surplus ITV6 CT 
(cc) 
Surplus ITV4DCT 
(cc) 
Ratio Surplus 
ITV6 CT/SUM ITVs 
Ratio Surplus 
ITV4DCT/SUM ITVs 
A 0.1 1.7 36.1 2.4 
B 1.8 2.9 19.4 11.8 
C 1.2 3.3 21.4 7.8 
D 2.5 6.3 16.3 6.3 
E 0.6 1.4 15.2 6.6 
F 0.4 0.9 22.4 10.1 
G 0.3 8.6 52.4 2.1 
H 1.2 1.3 15.5 15.3 
I 2.2 3.2 11.1 7.6 
J 7.8 5.9 10.0 13.2 
Mean - - 22.0 8.3 
SD - - 13.0 4.4 
Patient X Y Z 3D 
A 0.5 0.3 1.1 1.2 
B 0.4 1.7 2.1 2.7 
C 0.1 0.9 1.1 1.5 
D 0.3 1.1 0.7 1.3 
E 0.1 0.3 0.5 0.6 
F 0.7 2.0 0.3 2.1 
G 1.5 1.6 1.1 2.4 
H 1.1 1.7 0.6 2.1 
I 1.1 1.4 0.3 1.8 
J 0.4 1.5 0.5 1.6 
Mean 0.6 1.3 0.8 1.7 
SD 0.5 0.6 0.5 0.6 
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Dosimetric analysis 
When planning was performed using the PTV4DCT, full coverage of the PTV6 CT by the 
prescription 80% isodose was achieved in all patients (i.e. mean = 99.4%, minimum 
= 97.2%). When using the PTV6 CT, however, the mean coverage of the PTV4DCT by the 
80% isodose was only 92.5% of the volume, with a minimum of 77.7% and 77.5% in 
patients A and G, respectively (Table 6). 
 
 
 
 
 
Table 6. Dose coverage of both PTV6 CT and PTV4DCT when treatment planning was 
 performed on PTV6 CT or PTV4DCT, respectively 
 
 
 
Additionally, an analysis was performed using the PTVs10 mm, derived from each single 
MSCT expanded with a margin of 10 mm. Although these PTVs10 mm were on average 
twice the size of the other PTVs (Table 7), both the PTV4DCT and PTV6 CT were 
significantly underdosed, again in patients A and G (Table 8; Figure 3). 
 
 
Patient 
Coverage (volume %) of PTV6 CT with 
Planning on PTV4DCT 
Coverage (volume %) of PTV4DCT with 
planning on PTV6 CT 
 
80% 
isodose 
70% 
isodose 
60% 
isodose 
50% 
isodose 
80% 
isodose 
70% 
isodose 
60% 
isodose 
50% 
isodose 
A 99.8 100 100 100 77.7 86.2 89.7 92.7 
B 99.3 100 100 100 92.9 95.3 96.9 98.4 
C 100 100 100 100 97.6 99.5 99.9 99.9 
D 99.9 100 100 100 98.4 99.4 99.7 99.8 
E 99.8 100 100 100 96.7 97.7 99.6 100 
F 99.1 100 100 100 90.4 96.3 99.6 100 
G 100 100 100 100 77.5 86.5 91.6 95.3 
H 97.2 99.0 99.8 100 95.3 98.8 99.6 100 
I 99.9 100 100 100 99.9 100 100 100 
J 100 100 100 100 99.1 99.5 99.8 99.9 
Mean 99.5 99.9 100 100 92.6 95.9 97.6 98.6 
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Table 7. Volumes of three PTVs generated. 
Patient Mean PTV10 mm (cc) PTV6 CT (cc) PTV4DCT (cc) PTV10 mm/PTV6 CT PTV10 mm/PTV4DCT 
A 19.2 ± 1.3 7.0 10.7 2.8 1.8 
B 58.4 ± 4.9 23.8 25.8 2.5 2.3 
C 61.6 ± 0.8 23.3 26.6 2.7 2.3 
D 107.8 ± 5.9 53.7 58.8 2.0 1.8 
E 46.1 ± 2.1 16.5 17.4 2.8 2.7 
F 27.8 ± 1.8 7.9 9.1 3.5 3.1 
G 28.5 ± 2.9 18.3 31.2 1.6 0.9 
H 32.0 ± 3.0 14.2 14.5 2.3 2.2 
I 79.6 ± 10.4 42.1 44.4 1.9 1.8 
J 149.5 ± 5.9 81.1 79.7 1.8 1.9 
Mean - - - 2.4 2.1 
 
 
 
 
Table 8. Mean dose coverage of PTV4DCT and PTV6 CT with planning on PTV10 mm 
 
 
Discussion 
Far higher rates of local control have been reported in early stage NSCLC with the use 
of hypofractionated SRT, than achieved using other radiotherapy techniques [5-12]. 
Most authors used standard, population-based, margins for target definition [5, 6, 9, 
11]. However, an accurate individualized 3D definition of target volumes is a more 
appropriate prerequisite in view of the high doses per fraction and steep dose 
gradients characteristic of SRT. This is particularly the case, as tumor mobility does 
not clearly correlate with location in the lung [13-15]. 
Patient Mean coverage (volume%) PTV4DCT Mean coverage (volume%) PTV6 CT 
 
80% 
isodose 
70% 
isodose 
60% 
isodose 
50% 
isodose 
80% 
isodose 
70% 
isodose 
60% 
isodose 
50% 
isodose 
A 78.9 82.3 84.4 86.2 87.5 90.1 92.3 94.1 
B 99.9 100 100 100 100 100 100 100 
C 100 100 100 100 100 100 100 100 
D 100 100 100 100 100 100 100 100 
E 100 100 100 100 100 100 100 100 
F 100 100 100 100 100 100 100 100 
G 60.9 63.3 65.5 68.0 64.6 66.7 68.7 71.2 
H 96.6 97.3 98.3 99.0 96.4 97.4 97.8 98.9 
I 99.5 99.8 99.9 100 99.6 99.9 100 100 
J 100 100 100 100 100 100 100 100 
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As we are unable to perform respiration-gated SRT currently, and as patients with 
medically inoperable stage I NSCLC poorly tolerate breath-hold techniques due to 
poor pulmonary function, we chose to incorporate all tumor mobility into treatment 
planning.  Our approach for deriving ITVs had consisted of fusing GTVs from 6 rapid 
CT scans, as previous work had shown that ITVs derived from up to 3 rapid planning 
CT scans were smaller that those derived using 6 CT scans (including slow scans) [16, 
25]. Although the exact number of unmonitored scans required for reliable ITV 
definition is uncertain, the arbitrary choice of 6 was based upon practical 
considerations, i.e. to limit the scanning time and the labor-intensive co-registration 
process. Consequently, the availability of the 4D scans led us to quickly implement a 
technique that permitted the incorporation of all respiration-related movement. 
 
The present analysis compared target definitions based on the 6-scan method to that 
using a single 4DCT scan in a cohort of ten patients, half of whom had lower lobe 
lesions that exhibit greatest mobility [14]. Patients A and G had the most mobile 
tumors, and their ITV4DCT was considerably larger than the ITV6 CT (Table 2; Figure 2), 
indicating that 4D scans captured mobility that would have been otherwise missed.  
 
 
Figure 2. Patient A: Coronal and sagittal views of the ITVs generated using
 both the 6-scan technique (orange - ITV6 CT) and 4DCT scan (green -
ITV4DCT) 
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The results obtained using both the scanning techniques were comparable for the 
other 8 patients. Equally important was the dosimetric analysis showing the 
inappropriateness of using ‘standard PTVs’ obtained by expanding a single GTV6 CT 
with a 3D margin of 10 mm. Not only were such PTVs on average twice as large as 
the PTV6 CT and PTV4DCT, thereby resulting in increased normal tissue irradiation, both 
the highly mobile tumors were underdosed cranio-caudally (Figure 3). The addition of 
an anisotropic margin of e.g. 15 mm cranio-caudally and 10 mm in the other 
directions could have ensured adequate coverage of the PTV4DCT, but at the cost of an 
even larger irradiated volume. 
 
 
Figure 3. Patient A: ITV4DCT (green) versus that from a single “random” GTV6 CT 
 (pink) with added margin of 10 mm (PTV; orange) showing a failure of 
 the latter to cover the ITV4DCT caudally. 
 
 
 
 
 
 
 
 
 
 
Minimizing normal tissue irradiation in SRT by using 4DCT scans can reduce the risk of 
late normal tissue toxicity associated with hypofractionated SRT schemes using 3 
fractions of 20 Gy [5]. The reliable classification of tumors into non-mobile and mobile 
subgroups during treatment planning will identify patients who are candidates for 
more complicated techniques such as SRT using gating [26] or patient self-breath-
hold [27]. Although this analysis was limited to peripheral lung tumors, these data 
support the use of 4D scans in generating ITVs also for locally advanced lung tumors. 
The generation of a single 4DCT scan during quiet respiration is a relatively simple 
procedure, which poses no problems to patients with compromised respiratory 
function. As the respiratory signal is digitally ‘stamped’ on each CT slice, it is possible 
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to reconstruct CT slices retrospectively at several phases over the respiratory cycle, 
yielding a 4D dataset. Although the radiation exposure to patients from 4DCT 
scanning is relatively large (ranging from 0.02 to 0.09 Gy) in comparison to a single 
conventional CT scan, the substantially smaller target volumes derived from 4DCT 
scans in comparison to standard PTVs that will be treated with high-dose fractions, 
justify this additional exposure. Furthermore, as intensity-modulated radiotherapy 
(IMRT) (without respiratory gating) is best reserved for non-mobile lung tumors, 
4DCT scans can also identify candidates suitable for IMRT. However, data on the 
reproducibility of ITVs generated during a single session, as well as possible time-
trends during the course of treatment are unknown, but are the subject of ongoing 
research in our department. 
 
In conclusion, individualized assessment of tumor mobility can improve the accuracy 
of target definition in patients who are undergoing SRT for stage I NSCLC. Definition 
of the target volume based on a single CT scan with a margin of 10 mm is clearly 
inappropriate. A single 4DCT scan can replace the use of multiple unmonitored CT 
scans in defining individualized target volumes more accurately, in particular for 
highly mobile tumors. This approach can further improve tumor control and limit the 
likelihood of treatment-related toxicity. 
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Abstract 
Purpose: Single 4-dimensional CT (4DCT) scans reliably capture intra-fractional tumor 
mobility for radiotherapy planning, but generating internal target volumes (ITVs) 
requires the contouring of gross tumor volumes (GTVs) in up to 10 phases of a 4DCT 
scan, as is routinely performed in our department. We investigated the use of 
maximum intensity projection (MIP) protocols for rapid generation of ITVs. 
Methods and Materials:  4DCT data from a mobile phantom and from 12 patients with 
stage I lung cancer were analyzed. A single clinician contoured GTVs in all respiratory 
phases of a 4DCT, as well as in 3 consecutive phases selected for respiratory gating. 
MIP images were generated from both phantom and patient data, and ITVs were 
derived from encompassing volumes of the respective GTVs. 
Results: In the phantom study, the ratio between ITVs generated from all 10 phases 
and those from MIP scans was 1.04. The corresponding center of mass of both ITVs 
differed by less than 1 mm. In scans from patients, good agreement was observed 
between ITVs derived from 10 and 3 (gating) phases and the corresponding MIPs, 
with ratios of 1.07 ± 0.05 and 0.98 ± 0.05, respectively. In addition, the center of 
mass of the respective ITVs differed by only 0.4 and 0.5 mm.   
Conclusion: MIPs are a reliable clinical tool for generating ITVs from 4DCT datasets, 
thereby permitting rapid assessment of mobility for both gated and non-gated 4D 
radiotherapy in lung cancer. 
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Introduction 
Recent studies have shown that individualized planning margins are required to 
account for the variability and unpredictability of lung tumor mobility [1-4]. 4-
Dimensional (4D) radiotherapy has been defined as the explicit inclusion of temporal 
changes in anatomy during the imaging process, dose-planning and delivery of 
radiotherapy [5]. Such spatial and temporal information on tumor mobility can be 
derived with single CT scan procedures such as ‘slow’ CT scans [6-8] or respiration-
correlated 4DCT scans [9-11]. Both techniques allow for the generation of 
individualized internal target volumes (ITVs) [12] for treatment planning, but 4D 
scans have the added advantage of permitting the retrospective selection of phases 
for gated radiotherapy [10, 13].  
 
The need to contour tumors and/or normal organs in 10 or more phases of respiration 
is a major drawback to the routine clinical use of 4DCT scans. Our recent analysis 
revealed that significant changes in tumor volume can occur during fractionated 
stereotactic radiotherapy for stage I non-small cell lung cancer [14], which implies 
that repeat CT planning may be appropriate during 4D radiotherapy, thereby adding 
to the workload. Reliable auto-segmentation tools are not yet available and remain 
the subject of active ongoing research [15, 16]. We currently manually contour gross 
tumor volumes (GTVs) in all 10 phases of a 4D scan for planning stereotactic 
radiotherapy for stage I lung cancer and derive ITVs from the volume encompassing 
these GTVs [11].  
 
To reduce the workload of contouring multiple target volumes, we evaluated the post-
processing tools of maximum intensity projection (MIP) and minimum intensity 
projection (MinIP) for use with 4DCT datasets. Briefly, MIP projections reflect the 
highest data value encountered along the viewing ray for each pixel of volumetric 
data, giving rise to a full intensity display of the brightest object along each ray on the 
projection image. Conversely, MinIP projections reflect the lowest data value 
encountered along the viewing ray for each pixel of volumetric data. Both MIP and 
MinIP are standard volume rendering techniques used in diagnostic radiology [17-22], 
for example to extract high or low intensity structures such as blood vessels [18] from 
volumetric CT or MRI data. We compared ITVs derived from contouring GTVs in all 
respiratory phases (Figure 1a) with MIPs generated from 4DCT datasets (Figure 1b), 
for both a mobile phantom and patients. 
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Figure 1. Pixel-based intensity projection protocols from 4DCT datasets of a mobile 
tumor, illustrating (a) separate phases of the 4DCT, (b) maximum 
intensity projection, (c) minimum-intensity projection, and (d) mean 
intensity projection  
 
 
 
 
 
 
 
 
 
 
 
Materials and Methods 
4DCT procedure 
We routinely perform 4DCT scans for radiotherapy planning of lung tumors on a 
LightSpeed 16-slice CT scan (General Electric Company, Waukesha, WI) during quiet, 
uncoached respiration with an index and slice thickness of 2.5 mm. During the 
scanning procedure, respiratory signals are recorded using the Varian Real-Time 
Position Management (RPM) respiratory gating hardware (Varian Medical Systems, 
Palo Alto, CA). The RPM system uses infrared-reflecting markers on the upper 
abdomen, which are illuminated by infrared-emitting diodes surrounding a camera. 
The camera captures the marker motion, and a respiratory signal is recorded in 
synchronization with the X-ray ‘ON’ signal from the CT scanner. The scanner is 
operated in axial cine mode, with multiple scans performed at each couch position for 
a duration that is at least equal to the length of the patient’s respiratory cycle. Each 
image from the acquired dataset is sorted into one of ten phase bins using the 
Advantage 4DCT application running on an Advantage Workstation 4.1 (General 
Electric Company, Waukesha, WI). The phase bins are, to a good approximation, 
evenly spaced in time over the respiratory cycle. 
 
Motion phantom 
As the initial step, MIP and MinIP images were generated from the raw (i.e. non 
phase-sorted) data of 4DCT scans performed on a motion phantom, which consisted 
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of a human body-like torso with lungs and a bone equivalent spine model. The 
phantom was filled with water to have human body equivalent properties for CT 
scanning and dose measurements. A 3 cm large silicon tumor substitute attached 
rigidly to a metal cylinder was positioned in the left side of the phantom, which could 
move longitudinally by approximately 1.5 cm. For detecting an external breathing 
signal, a vertically movable board holding infrared reflective markers was mounted 
above the phantom chest. Both the board and the tumor were moved under computer 
control by independent servo drives, and the software permitted the simulation of a 
simple sinusoidal breathing curve. The silicon tumor substitute was contoured on both 
the MIP and MinIP datasets, and these results were compared with manual contouring 
of all 10 phases from the 4DCT scan. These target volumes were compared also to 
those generated using a ‘slow’ CT scan performed with a CT revolution time of 4 
seconds. 
 
Patient study 
A retrospective analysis was performed on 4DCT scans from 11 patients with 12 
relatively mobile peripheral stage I lung tumors that were treated with stereotactic 
radiotherapy (Table 1). The 3D mobility vectors of tumors were determined by manual 
contouring of GTVs in all phases of the 4DCT scans, and these ranged from 2.5 – 29.5 
mm. To evaluate the performance of the MIP software, we included tumors at 
different anatomic locations in the lung, including the hilus and lesions adjacent to the 
chest wall. GTVs were manually contoured on all 10 phases of the 4DCT scan using 
standard window/level settings. A window consisting of 3 consecutive phases at end-
expiration was selected for respiratory-gating. Manually contoured ITV10 phases and  
ITV3 phases were derived from the encompassing volume of the respective GTVs. 
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Table 1. Tumor characteristics 
 
 
MIP images were automatically generated using Advantage 4D software from the raw 
dataset of the 4DCT scan for both 10 phases and the same 3 respiratory-gating 
phases in each patient. The same clinician contoured ITVs on both the 10-phase 
(ITVMIP 10 phases) and 3-phase MIP scans (ITVMIP 3 phases). Similarly, MinIP images were 
generated and manually contoured to derive an ITVMinIP that represents the space 
where tumor is present during the entire respiratory cycle (Figure 1c). All MIP-based 
ITVs were compared to the corresponding manually contoured ITVs using the 
BrainLab planning system (Brainscan v. 5.2, BrainLab, Heimstetten, Germany). In 
order to limit radiation exposure, we did not perform slow CT scans in patients. 
Definitions of all different ITVs generated are summarized in Table 2. 
 
 
 
Table 2. Summary of different internal target volumes used 
 
 
 
Tumor T stage 
Mean GTV 
(cc) 
Location 
3D mobility 
vector (mm) 
A T1 3.9 Left lower lobe 23.6 
B T1 1.5 Right upper lobe 11.3 
C T2 8.1 Left upper lobe 4.3 
D T1 4.9 Left lower lobe 11.6 
E T1 3.3 Right upper lobe, adjacent to hilus 5.3 
F T1 2.1 Right upper lobe 10.9 
G T1 2.0 Left lower lobe, adjacent to hilus 12.0 
H T1 2.9 Left lower lobe 29.5 
I T2 37.2 Right lower lobe, adjacent to chest wall 24.2 
J T1 0.7 Left upper lobe 2.9 
K T1 2.3 Right upper lobe, adjacent to chest wall 2.5 
L T1 1.5 Left lower lobe 16.0 
Volume Definition 
ITV10 phases ITV derived from manual contouring of all 10 phases of the 4DCT 
ITV3 phases 
ITV derived from manual contouring of three consecutive phases at end-
expiration 
ITVMIP 10 phases ITV derived from a maximum intensity projection of all 10 phases of the 4DCT 
ITVMIP 3 phases 
ITV derived from a maximum intensity projection of 3 consecutive phases at end-
expiration 
ITVMinIP ITV derived from a minimum intensity projection of all 10 phases of the 4DCT 
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Results 
Phantom study 
Frontal reconstructions of the MIP and MinIP datasets generated from the 4DCT scans 
of the phantom are shown in Figure 2. A good correlation was observed between the 
fully contoured ITV10 phases and the corresponding ITVMIP 10 phases (Figure 3, left panel). 
The ratio of ITV10 phases and ITVMIP 10 phases was 1.04, and the distance between the 
center of mass of both ITVs was less than 1 mm (Table 3). Contouring of the volume 
that was common to all 10 4D phases (ITVoverlap 10 phases) corresponded well with the 
MinIP contours (ITVMinIP) (Figure 3, right panel). The ratio of ITVoverlap 10 phases and 
ITVMinIP was 0.93, and the distance between the centers of mass was less than 1 mm 
(Table 3). Similarly, the ratio of the ITVMIP 10 phases and the ITV derived with a slow CT 
scan was 1.08, with an absolute difference of 1.6 cc. The 3D shift between these ITVs 
was also less than 1 mm. 
 
 
Figure 2. Maximum intensity projection (left panel) and minimum intensity 
projection (MinIP) of the 4DCT scan of a mobile phantom. The arrow-like 
shape represents the mechanism used to generate movement of the 
silicon tumor substitute in the phantom 
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Figure 3. Projection of the ITVMIP 10 phases (red contour) on all ten contoured phases 
 of the 4DCT scan (yellow contours). On the right panel the contoured
 minimum-intensity projection dataset (purple contour) is projected on all 
 ten contoured phases of the 4DCT scan 
 
 
 
 
Table 3. Summary of data from the phantom study. The MIP-based ITV was 
compared to both ITV10 phases and ITVslow CT. The MinIP-ITV was compared 
to the common overlapping ITV of all 10 phases 
 
 
 
 
ITV10 phases 22.8 cc 
ITVMIP 10 phases 21.9 cc 
Ratio ITV10 phases/ITVMIP 0.96 
Distance between the two centers of mass (mm) 0.2 
  
ITVoverlap 10 phases 10.2 cc 
ITVMinIP 11.0 cc 
Ratio ITVoverlap 10 phases/ITVMinIP 0.93 
Distance between the two centers of mass (mm) 0.5 
  
ITVslow CT 20.3 cc 
Ratio ITVMIP 10 phases/ITVslow CT 1.08 
Distance between the two centers of mass (mm) 0.5 
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Patient study 
Similar comparisons were performed between contours of all phases of the 4DCT and 
the contoured MIP images of 12 tumors. As in the phantom study, good agreement 
was observed for both 10-phase and 3-phase ITVs, with the ratio of ITV10 phases/ITVMIP 
10 phases being 1.07 ± 0.05, and the ratio ITV3 phases/ITVMIP 3 phases being 0.98 ± 0.05 
(Table 4). Relative differences between these ITVs in excess of 10% were observed in 
relatively small tumors, but the absolute differences were smaller than 1 cc in all 
cases. The mean distance between the center of mass of manually contoured and 
MIP-based ITVs was 0.4 and 0.5 mm for the 10 and 3 phases, respectively.  
 
 
Table 4. Data from 12 patients comparing MIP-based ITVs with ITV10 phases and  
  ITV3 phases, respectively 
 
  
Because a MIP-based ITV represents the volume where the tumor is present at any 
time within the respiratory cycle, and a MinIP-based ITV represents the volume where 
the tumor is present during the entire respiratory cycle, the ratio of these ITVs gives a 
measure of respiratory-induced tumor mobility. This ratio (ITVMinIP/ITVMIP 10 phases) was 
correlated with the mobility vector derived from all 10 phases of the 4DCT scan. In 
two patients with highly mobile, small tumors with an intra-fractional mobility of more 
than 20 mm, the ITVMinIP/ITVMIP ratio was zero, because no tumor at all was visible on 
the MinIP projections (Figure 4). Analysis of all patient data revealed a correlation 
coefficient (R) of 0.72 for the relation between 3D mobility vector and ITVMinIP/ITVMIP 10 
phases ratio. The ratio ITVMinIP/ITVMIP 10 phases is, however, determined also by the 
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absolute ITV volume, which is illustrated in tumors ‘A’ and ‘I’ with comparable 3D 
mobility vectors, but largely different ITV volumes (Table 1). In all 7 patients with an 
ITVMinIP/ITVMIP 10 phases ratio of less than 0.25, the mobility vector was more than 10 mm 
(Figure 5). 
 
 
 
Figure 4. Maximum intensity projection image of a highly mobile tumor in the left 
lower lobe (left panel), with the corresponding minimum intensity 
projection image (right panel) that showed no location where tumor was 
present during all respiratory phases 
 
 
 
The ratio ITVMinIP/ITVMIP 10 phases correlated even more strongly (R=0.95) with the 
reduction in ITV volume that can be achieved with respiratory-gating, i.e. with the 
ratio ITV3 phases/ITV10 phases (Figure 6). This indicates that the former ratio can be used 
clinically for rapidly identifying patients who can benefit from respiration-gated 
radiotherapy.  
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Figure 5. Relationship between the 3D mobility vector and the ratio between the 
ITVMinIP and ITVMIP 10 phases. The letters correspond to patients referred to in 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Relationship between the reduction in ITV (%) obtained with respiratory 
gating and the ratio between ITVMinIP and ITVMIP 10 phases 
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Discussion 
4D radiotherapy represents an exciting development as it allows for radiotherapy to 
be individualized for the patient in question. However, 4DCT scans generate up to 10 
times more data (and contouring work) than a single conventional planning CT scan. 
Our technique for 4DCT scanning involves acquiring multiple images at each couch 
position during quiet respiration. MIP or MinIP post-processing of the ‘raw unsorted 
data’ of these 4DCT scans results in the display of the maximum or minimum intensity 
of each pixel in the stack of axial CT images at each table position. As such, MIP 
datasets represent composite images with phase summation or compression of tumor 
positions during all phases of respiration, thereby allowing for direct generation of 
ITVs.  
 
In both the phantom study and patient data, MIP–based ITVs showed an excellent 
agreement with ITVs derived from contouring GTVs on all selected phases of the 
4DCT. The generation and contouring of a MIP image took less than 10 minutes per 
patient, and resulted in individualized ITVs. Speed was also enhanced by the fact that 
the technique of 4D scanning requires no co-registration of different 4D phase bins. 
The clinical introduction of the MIP technique has significantly reduced our clinical 
workload associated with treatment planning for peripheral lung tumors. 
 
The MIP technique also facilitates the evaluation of plans for gated radiotherapy by 
permitting quick generation of ITVs in selected phases of respiration. Our recent 
analysis of 43 patients with stage I NSCLC found that only 25% of patients had 
mobility of sufficient magnitude (>1 cm) as to derive a benefit from gating [13]. 
However, determining mobility required contouring of all ten phases of the 4DCT scan. 
The present analysis revealed that the ratio of ITVMinIP/ITVMIP 10 phases correlates well 
with the reduction in ITV that resulted from selecting 3 phases in end-expiration for 
respiratory gating. As such, this simple two-step approach will facilitate the selection 
of suitable patients for gated radiotherapy in a fast and objective manner. 
 
The minor discrepancies observed in ITVs generated using the two techniques can be 
accounted for by contouring variations, particularly as the displacement of the center 
of mass of both ITVs was less than 1 mm in all cases. Inter-clinician variability was 
not a confounding variable, because a single clinician performed all contouring. It can 
Use of maximum intensity projections (MIP) for target volume generation in 4DCT scans for lung cancer 
 
 39 
be expected that the availability of reliable auto-segmentation tools could further 
simplify ITV generation [16, 23]. 
 
‘Slow’ CT scanning is also a single-step method for generating of ITVs in lung cancer 
[2, 6, 8]. This technique uses a CT revolution time of 4 seconds, which allows for the 
incorporation of tumor mobility into the CT images. However, slow CT scans are only 
suitable for peripheral lung tumors where the contrast between tumor and normal 
lung tissue is high. In addition, as the pixel-intensity in slow CT images is proportional 
to the period of time that the tumor is at its extreme positions, tumor borders tend to 
be smeared. In this manner, slow CT scans more resemble mean intensity projection 
images, which can also be acquired from 4DCT scans (Figure 1d). Our current 
software does not allow for the generation of mean intensity projection, but this will 
become possible in a future release. Figure 7 shows a comparison between such a 
slow CT scan (left panel) and a mean intensity projection scan (middle panel) 
generated for the mobile phantom. In contrast, the selection of maximum intensities 
in MIP scans (right panel) results in a relatively high contrast between ‘tumor’ 
boundaries and surrounding normal tissues, which allows for easier contouring. The 
more “blurred” ITV borders obtained with slow CT scanning may account for the 8% 
difference between MIP- and slow CT-based ITVs. 
 
 
Figure 7. Scans of the mobile phantom showing a slow CT scan (left panel), a 
mean intensity projection (middle panel), and a maximum intensity 
projection (right panel). Note the inhomogeneous intensity in the 
direction of mobility with the slow CT scan and the mean intensity 
projection 
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Some potential drawbacks of using MIP projections must be appreciated. Because MIP 
scans do not reflect the appropriate lung density for treatment planning, the latter has 
to be performed on a co-registered planning CT, e.g. a single phase of the 4D scans. 
In addition, MIP may not fully display mobile structures if an adjacent structure has 
equal or greater density. A number of tumors included in this study were in contact 
with the thoracic wall or the hilus. Although these sites did not complicate contouring 
on the MIP scans, it must be acknowledged that only reasonably well-demarcated T1-
2 tumors were accepted for stereotactic radiotherapy. However, we recently 
encountered a problem with MIP scans in a patient whose tumor was located directly 
adjacent to the diaphragm. MIP images failed to visualize the caudal extent of the 
ITV10 phases as a result of overlap with the high-density diaphragm (Figure 8). This 
important pitfall when directly generating ITVs from MIP scans can be avoided by 
reviewing the GTVs at extreme phases of the 4DCT in tumors that are adjacent to the 
thoracic wall, mediastinum, heart or diaphragm. The issue of whether MIP images also 
reliably allow for contouring planning volumes for organs at risk is the subject of 
ongoing research. 
 
In conclusion, the generation of MIP scans is a reliable and fast clinical tool for 
generating ITVs from 4DCT datasets, thereby permitting rapid assessment for both 
gated and non-gated 4D radiotherapy for early stage lung cancer. 
 
 
Figure 8. (a) Example of a tumor located adjacent to the diaphragm, which was
 not fully visible on repeated MIP scans as a result of the overlap with the 
 diaphragm. (b) The extreme end-inspiration tumor position was visible 
 on the corresponding single phase scan. (c) MIP information on this 
 patient would underestimate the caudal extension of the ITV (orange and 
 pink contours), compared with an ITV10 phases (green contour). 
 
 
 
 
 
 
(a) (b) (c) 
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Abstract 
Purpose: High local control rates have been reported with stereotactic radiotherapy 
(SRT) for stage I non-small cell lung cancer. As high dose fractions are used, 
reduction in treatment portals will reduce the risk of toxicity to adjacent structures. 
Respiratory gating can allow reduced field sizes and planning 4DCT scans were 
retrospectively analyzed in order to (1) study the benefits for gated SRT, and (2) 
identify patients who derive significant benefit from this approach. 
Methods and Materials: A total of 31 consecutive patients underwent a 4DCT scan, in 
which 3D CT datasets for 10 phase bins of the respiratory cycle were acquired during 
free breathing. For a total of 34 tumors, the 3 planning target volumes (PTVs) were 
analyzed, namely [a] PTV10bins, derived from an internal target volume (ITV) that 
incorporated all observed mobility (ITV10bins), with the addition of a 3 mm isotropic 
setup margin, [b] PTVgating, derived from an ITV generated from mobility observed in 3 
consecutive phases (‘bins’) during tidal-expiration, plus addition of a 3 mm isotropic 
margin, and [c] PTV10mm, derived from the addition of a 10 mm isotropic margin to the 
most central GTV in the 3 bins selected for gating.  
Results: The PTV10bins and PTVgating were on average 48.2% and 33.3% of the PTV10mm, 
and respective mean volumes of normal tissue (outside the PTV) receiving the 
prescribed doses were 57.1% and 39.1%, respectively, of that PTV10mm. A significant 
correlation was seen between the extent of tumor mobility (i.e. a 3D mobility vector 
of at least 1 cm) and reduction in normal tissue irradiation achieved with gating. The 
ratio of the union and intersection of the tumor volumes at extreme phases of tidal 
respiration predicted for the benefits of gated respiration. 
Conclusion: The use of ‘standard population-based’ margins for SRT leads to 
unnecessary normal tissue irradiation. The risk of toxicity is further reduced if 
respiration-gated radiotherapy is used to treat mobile tumors. These findings suggest 
that gated SRT will be of clinical relevance in selected patients with mobile tumors.
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Introduction 
In patients presenting with stage I non-small cell lung cancer (NSCLC), far higher 
local control rates have been reported using stereotactic radiotherapy (SRT) [1-8] 
than have been reported with conventional fractionated radiotherapy [9]. SRT 
generally combines high-precision irradiation with high fraction doses, and total 
biological doses well in excess of 100 Gy. Although the reported clinical toxicity after 
SRT for lung cancer is low, this may reflect both patient selection (e.g. small 
peripheral lung cancers) and a relatively short period of follow-up in most series. The 
high dose per fraction used can result in toxicity to normal lung tissue and adjacent 
structures such as the esophagus, spinal cord and thoracic wall [10], and it is 
therefore important that treatment portals for SRT should remain as small as possible. 
As most SRT approaches utilize online setup correction protocols, measures to reduce 
the margins used to account for tumor mobility offer a possible solution for minimizing 
toxicity. 
 
Recent studies show that individualized, and not standard population-based margins, 
are necessary for high-precision radiotherapy of stage I NSCLC [11, 12]. Approaches 
such as breath-hold techniques and respiration-gated radiotherapy have been used to 
reduce target volumes for lung cancer [13, 14]. However, breath-hold techniques are 
often poorly tolerated by patients with lung cancer [13]. Respiratory gating permits a 
reduction in field sizes, as irradiation can be limited to phases in which the mobile 
target volume is in a predetermined position. Commercially available gating systems, 
e.g. the Varian Real-Time Position Monitor (RPM), are already in clinical use [15].  
 
For SRT planning in stage I NSCLC, use of a single 4-dimensional (4D) or respiration-
correlated CT scan was superior to the use of multiple conventional CT scans [16]. As 
our 4DCT scan technique also uses RPM gating equipment for co-registering 
respiratory signals, we analyzed 4D scans of 31 patients in order to (1) establish the 
benefit with use of respiratory gating in SRT, and (2) establish the criteria for 
identifying patients who could derive significant benefit from this approach. 
 
Materials and Methods 
A total of 34 tumors in 31 consecutive patients with stage I NSCLC, who were treated 
with fractionated SRT using 4DCT scans at the VU University medical center 
Amsterdam, were included in this study.  
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4DCT scanning procedure  
Our current technique for generating internal target volumes (ITVs) for SRT of stage I 
NSCLC involves the use of a single 4DCT scan performed during quiet uncoached 
respiration. Patients are positioned supine, with the arms positioned above the head 
on an adjustable arm support. The RPM respiratory gating hardware (Varian Medical 
Systems, Palo Alto, CA) used for recording the breathing pattern entails placement of 
a lightweight block containing 2 reflective markers on the upper abdomen. Infrared 
light from an illuminator is reflected from the markers, and captured by a camera.  
 
Our 4DCT scanning protocol for lung tumors on the Lightspeed 16 slice CT scanner 
simultaneously generates 8 contiguous slices of 2.5 mm for a 2 cm total longitudinal 
coverage per gantry rotation. The scanner is operated in axial cine mode. At each 
couch position, data are acquired for at least the duration of one respiratory cycle of 
the patient, after which the couch is advanced to the next position. Data acquisition 
ceases during couch movement, and a full 4DCT scanning procedure of the thorax 
takes about 90 seconds.  Retrospective sorting of the images into spatio-temporally 
coherent volumes is performed using the Advantage 4D software [GE Medical 
Systems, Waukesha, WI]. Each reconstructed image is assigned to a specific 
respiratory phase (or ‘bin’) based on the temporal correlation between surface motion 
and data acquisition. Following the acquisition of a 4DCT scan, Advantage 4D software 
is used to resort images into 3D bins at 10 selected respiratory phases. Motion was 
assessed by reviewing the sorted data using 4D viewer software, which was used to 
identify the extremes of mobility.  
 
The bins that represented 10 phases of respiration were imported into the BrainLab 
stereotactic radiotherapy planning system (Brainscan ver. 5.2, BrainLab AG, 
Heimstetten, Germany). As all 10 bins were derived from one single CT acquisition, 
image registration of the imported data sets (4D bins) on bony structures is not 
necessary.  
 
Deriving target volumes 
Gross tumor volumes (GTVs) were contoured in each of the 10 4D bins using 
standardized lung window level settings (Level=-500, Width=1000) by the same 
clinician in order to minimize contouring variations. All contours were automatically 
projected onto the first ‘bin’ of the 4DCT set, which was used for further analysis. As a 
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result of the high biological doses used with SRT, we and others apply no separate 
GTV to CTV margins for this indication [1, 17]. The actual internal target volumes 
used for SRT treatment planning were the volumes encompassing the GTVs from all 
10 bins of the 4DCT scan (ITV10bins). 
 
As gating prolongs the treatment time, it is common to use a ‘gate’ that allows a duty 
cycle of between 20-40% of respiration [13]. Consequently, we selected 3 consecutive 
‘gating bins’ during tidal-expiration by viewing the axial, frontal and sagittal 
reconstructions of all contoured GTVs. The encompassing volume of these 3 selected 
bins, labelled ITVgating, was contoured separately for each patient. Planning target 
volumes (PTVs) were derived from ITV10bins and ITVgating by adding a 3-dimensional 
isotropic setup margin of 3 mm, which is used for extracranial SRT on the Novalis 
ExacTrac system (BrainLab AG, Heimstetten, Germany). A ‘conventional’ PTV was 
derived from the addition of an isotropic GTV-PTV margin of 10 mm to the most 
central GTV of the 3 bins used for respiratory gating (PTV10mm). A volumetric 
comparison was made between the PTV10mm, PTV10bins and PTVgating derived from the 
abovementioned definitions. 
 
Dosimetry 
The dosimetric consequences of using either PTV10mm, PTV10bins or PTVgating were 
studied with the same beam configuration as was used for the actual patient 
treatment. This treatment plan, which was based upon PTV10bins consisted of 8-12 
individually optimized non-coplanar beams with 3 mm micro-multileaf collimation. The 
beam energy was 6 MV and the equivalent path length algorithm was used for tissue 
inhomogeneity correction. The clinical SRT fractionation schemes used were 3 
fractions of 20 Gy, 5 fractions of 12 Gy, or 8 fractions of 7.5 Gy, prescribed to the 
80% isodose and dependent on the location and size of lesion. As clinical toxicity 
parameters for normal tissues are not well established for such SRT schemes, the 
dose to normal tissues was evaluated as a percentage of the prescribed dose. Dose-
volume histogram (DVH) analysis was used to determine the volume of normal tissue 
within the high-dose region, which was defined by 40% and 80% isodoses. 
 
Analysis of mobility 
3D mobility vectors were derived for each tumor using the X, Y, and Z coordinates of 
the center of mass for each bin of the 4DCT scan, as derived from the Brainscan 
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software. In addition, the residual mobility in the 3 bins selected for respiratory gating 
was determined. These mobility vectors were correlated with the reductions in 
PTV10bins and PTVgating, respectively. As generating mobility vectors requires that all ten 
bins of the 4DCT scan be contoured, a less time-consuming method was investigated 
by first identifying the extremes of mobility using Advantage 4D software. After 
contouring only the GTVs on these 2 bins, the ratio of the intersecting and the 
encompassing volumes of these extreme phases was determined. A value close to 1 
indicated the relative absence of mobility. 
 
 
Results 
A total of 34 tumors were analyzed. Tumor characteristics are shown in Table 1. There 
were 24 T1No tumors (70.6%) and 10 T2N0 tumors (29.4%). The mean GTVs of T1 and 
T2 tumors were 4.8 cc and 27.3 cc, respectively. Included were 11 lower lobe tumors, 
22 upper lobe tumors, and 1 middle lobe tumor, and 8 tumors were adjacent to the 
pleura. 
 
Analysis of PTVs 
Review of all absolute and relative PTVs revealed PTV10mm to be the largest in all 
patients (Figure 1a-1b). Use of an individualized PTV10bins led to an average volume of 
48.2 ± 14.3% (SD) of the PTV10mm. The PTVgating was even smaller, with an average 
value of 33.3 ± 9.6% of the PTV10mm. The mean PTVgating was 70.5 ± 15.7% of the 
PTV10bins. 
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Table 1. Tumor characteristics 
 
 
 
 
Tumor Stage Tumor location 
1 T1N0M0 Left upper lobe 
2 T1N0M0 Left upper lobe 
3 T1N0M0 Left upper lobe 
4 T1N0M0 Right upper lobe 
5 T1N0M0 Right upper lobe 
6 T1N0M0 Right upper lobe 
7 T1N0M0 Right upper lobe 
8 T1N0M0 Left upper lobe 
9 T2N0M0 Right upper lobe 
10 T2N0M0 Left upper lobe 
11 T1N0M0 Right upper lobe 
12 T1N0M0 Right upper lobe 
13 T1N0M0 Left upper lobe 
14 T1N0M0 Right upper lobe 
15 T1N0M0 Left upper lobe 
16 T1N0M0 Left upper lobe 
17 T2N0M0 Left upper lobe 
18 T1N0M0 Right middle lobe 
19 T1N0M0 Left lower lobe 
20 T1N0M0 Left lower lobe 
21 T1N0M0 Left lower lobe 
22 T2N0M0 Right lower lobe 
23 T1N0M0 Left lower lobe 
24 T2N0M0 Right lower lobe 
25 T1N0M0 Right lower lobe 
26 T1N0M0 Left lower lobe 
27 T2N0M0 Right upper lobe; adjacent to pleura 
28 T2N0M0 Right upper lobe; adjacent to pleura 
29 T2N0M0 Left lower lobe; adjacent to pleura 
30 T2N0M0 Right upper lobe; adjacent to pleura 
31 T1N0M0 Left lower lobe; adjacent to pleura 
32 T2N0M0 Right upper lobe; adjacent to pleura 
33 T1N0M0 Right upper lobe; adjacent to pleura 
34 T1N0M0 Right lower lobe; adjacent to pleura 
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Figure 1a. Absolute volumes of PTVgating (), PTV10bins () and PTV10mm (  ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1b. Relative volumes of PTVgating (), PTV10bins () and PTV10mm (  ) 
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Irradiated normal tissue volumes   
The relative volumes of normal tissue encompassed by the 80% isodose were 
compared using treatment planning (Figure 2). The mean volumes of normal tissue, 
that were encompassed by the 80% isodose when PTV10bins and PTVgating were used, 
were 57.1 ± 18.0% and 39.1 ± 11.5% of the PTV10mm, respectively. A similar pattern 
was observed for the volume of normal tissue receiving 40% of the dose (data not 
shown). A typical example of the dose reductions in normal tissues achieved with 
gated radiotherapy for a mobile tumor is illustrated in Figure 3.  
 
 
 
 
 
Figure 2. Relative volume of normal tissue encompassed by the 80% isodose with 
  treatment planning on PTVgating (), PTV10bins (). All values are relative
  to PTV10mm (  ) 
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Figure 3. Example (case 21) of reduction in volume of normal tissue (in this case
 chest wall and lung tissue) in high-dose area (80% isodose) with 
treatment planning on PTV10bins and PTVgating. 
 
 
 
 
 
 
 
 
 
 
 
 
Residual mobility with gating 
It is desirable that the residual motion in phases selected for gating is kept small. The 
mean 3D mobility vector for all 10 bins was 8.5 ± 6.5 mm, and it decreased to 1.4 ± 
0.7 mm in the 3 gating bins (Figure 4). The corresponding values for tumors of the 
lower lobe were 13.5 ± 8.8 mm, with a decrease to 1.7 ± 0.9 mm with gating. 
 
Figure 4. 3D mobility vectors derived from 10 bins () versus gating window (3 
  bins; ) 
 
PTV10bins PTVgating 
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Tumor mobility versus dosimetric gain with gating 
As expected, a clear correlation was seen between the size of the 3D mobility vector 
and reduction in target volumes obtained using 4DCT scans and gating, respectively 
(regression coefficient R2 = 0.61; Figure 5). This trend was observed for both T1 and 
T2 tumors, although relatively few T2 patients had relatively large 3D mobility 
vectors. 
 
Pre-selection of patients for gated SRT 
A simplified method was investigated for identifying suitable patients for gating. The 
ratio of the intersecting and the encompassing volume of the GTV in extreme phases 
during tidal in- and expiration showed a high regression coefficient of 0.88 (Figure 6). 
This is a less laborious approach than using 3D mobility vectors derived from GTVs 
contoured on all ten bins. If a PTV reduction of at least 50% is used to select 
candidates for respiratory-gated SRT, only 14.7% (5 patients) of our patients would 
have been eligible. 
 
 
Figure 5. Reduction (%) of PTVgating compared to PTV10bins versus size of 3 D 
  mobility vector 
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Figure 6. Relation between the ratio of the intersecting/encompassing volume of
  GTVs in extreme phases of respiration and PTV reduction obtained with
  gating 
 
 
 
Discussion 
The reduction of the planning margins required to account for tumor mobility is the 
subject of active, ongoing research. The majority of patients with stage I NSCLC who 
are referred for radiotherapy are ineligible for surgery due to poor pulmonary function 
[18], and this explains an inability to tolerate procedures such as DIBH in up to 50% 
of patients [13]. As such, passive respiration-gated radiotherapy would appear to be 
an ideal approach for reducing the risk of normal tissue toxicity in this patient 
population.  
Early reports on the implementation of respiration-gated radiotherapy for lung tumors 
described the use of fluoroscopy for selecting phases for respiratory gating [19-21]. 
However, fluoroscopy does not permit accurate 3D determination of mobility for lung 
tumors in radiotherapy planning [22]. The use of 4DCT scans, on the other hand, 
enables a full characterization of tumor mobility and better detects mobility than even 
6 consecutive conventional CT scans [16]. As our technique for 4DCT scanning also 
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uses the RPM respiratory gating system, the 4D datasets obtained permit a rapid, 
patient-specific analysis of tumor mobility, and of the potential gains from gating.  
 
Recent work has shown that the use of standard margins result in inadequate target 
coverage for a proportion of patients with lung cancer [11, 16, 23, 24]. In comparison 
to PTVs generated using a ‘standard’ GTV to PTV margin of 10 mm, our analysis 
reveals that use of individualized margins (either PTV10bins or PTV3bins) allows for 
significant reductions in both PTV and mean volume of normal tissues within the 80% 
to 40% isodose. These findings reinforce the inappropriateness of standard mobility 
margins in SRT for lung cancer. 
 
We analyzed gating using 3 consecutive phases at end-tidal expiration in order to 
yield a 30% treatment window, which in turn reduced the mean 3D tumor mobility 
vector from 8.5 mm to 1.4 mm. However, as the delivery of gated SRT can take up to 
1-2 hours [17], use of larger gating windows may be more patient-friendly. When the 
cine-movies of 4DCT’s and the GTVs on all contoured bins were reviewed, a larger 
gating window appeared possible for some patients without undue increases in PTV. 
Our planning study assumed that gated radiotherapy at the end-expiratory phase was 
optimal for this patient group. Gating at end-expiration permits longer duty cycles, 
and is facilitated by the fact that the expiratory phase is more reproducible [19, 20, 
25]. The RPM system also permits gating based upon amplitude of the respiratory 
waveform, and the relative benefit of this approach remains to be investigated using 
4DCT scans. 
When compared to the PTV10bins, use of gating would have reduced PTVs by more than 
30% in 38% of tumors, and by more than 50% in 15% of tumors. As expected, these 
gains from gating were greatest in mobile tumors, which we arbitrarily defined as 
those with a 3D mobility vector of 1 cm or more. Such tumors comprised 32% (11 out 
of 34) of our tumors, and comparable figures for mobility have been reported by 
others. For example, analysis of data generated during tumor-tracking found that 11 
of 41 measured tumor trajectory datasets showed a maximum peak-to-peak motion 
of 1 cm [26]. An analysis using multiple CT scans reported that 44% of all tumors 
showed a 3D mobility of more than 1 cm, and more than 50% of such tumors were 
located in the lower lobe [11]. 
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A simplified method for identifying mobile tumors in 4DCT datasets was established by 
contouring only the 2 respiratory bins at the extremes of tidal respiration, after these 
phases were identified using 4D viewing software. The measure of tumor overlap 
between these two phases was shown to have a high predictive value for tumor 
mobility and, consequently, can be used to identify patients in whom addition 
treatment planning for respiration-gated radiotherapy is warranted. A reliable 
threshold to define which patients are suitable for respiratory-gating is difficult as this 
is not only dependent on the PTV reduction, but also on the absolute volume of the 
PTV. Furthermore, the incidence of toxicity with high-dose radiotherapy for stage I 
NSCLC is low. We defined a threshold of at least 50% PTV reduction as a potential 
indication for respiration-gated SRT. Although a volumetric reduction was observed for 
most cases, this threshold would indicate a clear benefit for respiratory-gating in only 
5 patients (14.7%). 
 
A number of limitations of the present study are being addressed in our ongoing work. 
Despite reduced normal tissue irradiation with respiratory gating, it remains to be 
established if reproducible target volumes can be derived from 4DCT scans generated 
using the RPM system. Our patients were scanned during uncoached quiet respiration 
after a reproducible pattern of respiration was observed. Previous work suggests that 
indirect tumor tracking by means of external breathing signals and/or diaphragmatic 
movements may fail to reflect actual 3D movements in some patients [27]. Repeat 
4DCT scans performed during SRT are currently being analyzed in order to establish 
the reproducibility of both breathing patterns, as well as tumor position.  
 
With interventions such as gating, direct visualization of tumor at the treatment unit 
offers a major advantage by permitting verification of target position, and identifies 
potential time-trends. Recent advances such as cone-beam CT scans and tomotherapy 
are ideal for this purpose [28], although gated imaging will have to be made possible 
for such devices. Until such time as gated imaging at the linear accelerator becomes 
available at our center, we will evaluate gating only in patients who have implanted 
fiducial markers that permit online tumor visualization. 
 
The amplitude and frequency of the respiratory signal can be variable during free 
breathing, and training using visual feedback and/or audio prompting has been shown 
to increase the gating window [29]. We are currently investigating the use of coaching 
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for the delivery of gated SRT in stage I lung cancer, and this could alter the relative 
benefits of gating. We are aware that inaccuracies of the calculation algorithm in 
dealing with electron transport in lung tissue exist, and penumbra broadening in lung 
tissue is not adequately accounted for [30]. For our planning study multiple 
intersecting 6 MV photon beams were used with dose prescription to the 80% isodose, 
so that such inaccuracies are unlikely to influence our conclusions. Current 
radiotherapy planning systems are unable to perform actual time-weighted dose 
calculation on 4DCT scans, which would also require to take respiratory changes in 
total lung volume into account. Our planning study was therefore performed on the 
first phase of the 4DCT scan in order to allow a reliable dosimetric comparison. Other 
important technical aspects of gated delivery are outside the scope of our study. 
 
In conclusion, analysis of this 4DCT database again highlights the inappropriateness of 
using ‘standard population-based’ margins for stage I NSCLC. Respiration-gated 
radiotherapy significantly reduces normal tissue irradiation when mobile tumors are 
treated. Further data on the reproducibility of respiratory waveforms (and tumor 
position), as well as on-line tumor visualization, will facilitate the clinical use of gated 
radiotherapy. As was recently pointed out, the worst intervention for mobility is one 
that falsely reassures and increases the chance of a geographic miss [31]. 
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Abstract 
Purpose: To identify potential time trends in target volumes and tumor mobility after 
stereotactic radiotherapy (SRT) for stage I non-small cell lung cancer.  
Patients and methods: Repeat planning CT scans were performed for 40 tumors 
during fractionated SRT delivered in either three (n=21), five (n=14) or eight 
fractions (n=5). The planning CT scans used to define internal target volumes (ITVs) 
consisted of either 6 multi-slice CT scans or a single 4DCT scan. All repeat CT scans 
were co-registered with the initial (D0) scan to determine volumetric or spatial 
changes in target volume, and tumor mobility vectors were determined from each 
scan. 
Results: A significant decrease in target volumes (ITVs and GTVs) relative to baseline 
values was observed starting at the fourth week of SRT (p=0.015). No trends in 
tumor mobility were detected during SRT. Significant positional shifts in the ITV, of 
more than 5 mm, were seen in 26-43% of patients at different times during SRT.  
Conclusion: Significant changes in target volumes can occur during SRT for stage I 
NSCLC. A failure to account for such changes, e.g. by repeat CT-planning or 
verification using on-board volumetric imaging, can lead to inadequate target 
coverage.
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Introduction 
The optimal approach for defining internal target volumes (ITVs) for mobile tumors 
such as lung cancer is the subject of active research [1]. Individualized assessment of 
tumor mobility has been shown to be necessary for lung tumors [2-4], and such 
individualized ITVs can be derived using slow scans [5], multiple computed 
tomography (CT) scans [6] or four-dimensional CT (4DCT) scans [7]. Despite a 
potentially major impact on local control, the reproducibility of ITVs for lung cancer 
during the entire course of treatment has not been well studied. An analysis of 
electronic portal images obtained during conventional radiotherapy reported ‘tumor 
shrinkage’ of 20% or more, in 40% of patients [8]. However, portal images are 
unsuitable for accurate volumetric or spatial assessment, and an evaluation using CT 
scans found the response to conventional radiotherapy or chemo-radiotherapy to be a 
slow process, with tumor volumes reaching their nadir 11 months after treatment 
completion [9].  
 
The issue of target reproducibility is of critical importance for high-dose 
hypofractionated treatment regimens such as stereotactic radiotherapy (SRT). Local 
control rates of approximately 85-90% have been reported after SRT for lung cancer 
[10-15], which are in marked contrast to those achieved with conventional 3-
dimensional conformal (3D) radiotherapy [16,17].   
Repeat planning CT scans performed before each fraction of pulmonary SRT revealed 
that the target coverage was below 95% of the prescribed dose in 9% of patients 
[18]. In view of this, as well as potential time trends in target volumes and changes in 
respiratory patterns, we elected to perform repeat treatment planning during SRT in 
all patients with stage I non-small cell lung cancer (NSCLC). The aim of the present 
study was to investigate inter-fractional changes in target volumes and tumor mobility 
during this 3- to 5-week period of SRT. 
 
Materials and Methods 
A retrospective analysis was performed on all treatment planning CT scans performed 
for SRT in 37 patients, who had a total of 40 stage I NSCLC. Tumor and treatment 
characteristics, including the overall treatment time, are summarized in Table 1. 
Before SRT, all patients underwent a setup procedure at the Novalis linear accelerator 
(BrainLab AG, Heimstetten, Germany). Adjustable arm support, as well as knee and 
ankle supports were used. The Novalis ExacTrac system of online setup correction 
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using both external reference markers and kilovolt images was used for stereotactic 
treatment. In the first 15 patients, the routine CT scanning procedure for deriving 
ITVs consisted of a single uncoached multislice CT scan (MSCT) of the entire thorax 
during quiet respiration, followed by five similar scans that were limited to the tumor 
region. All subsequent patients underwent a single respiration-correlated or 4DCT 
scan [7]. In view of the number and size of fractions delivered, and reports of the 
inadequacy of an initially defined PTV [18], CT planning was generally repeated before 
each weekly fraction in patients undergoing a three- or five-fraction scheme, and in 
the second week when the 8-fraction scheme was used. The indications for use of the 
different fractionation schemes are summarized in Table 2. Each subsequent fraction 
was planned and delivered using the most recent planning CT scan. 
 
Multiple MSCT technique 
The multiple spiral MSCT scans were performed during quiet uncoached respiration on 
a 16-slice GE Lightspeed CT scanner (GE Medical Systems, Waukesha, WI) with a slice 
thickness of 2.5 mm and an index of 2.5 with contiguous reconstruction. Co-
registration of all CT scans (one full range scan and five limited to the tumor region) 
from any given time during treatment was performed using the image-fusion software 
from the stereotactic planning system (Brainscan version 5.2, BrainLab, Heimstetten, 
Germany).  
 
4DCT scanning technique 
4DCT scanning was performed during quiet uncoached respiration on the 16-slice GE 
Lightspeed CT scanner using the Varian Real-Time Position Management (RPM) 
respiratory gating hardware for recording of the breathing pattern (Varian Medical 
Systems, Palo Alto, CA) and 4D imaging software (Advantage 4D, GE Medical 
Systems, Waukesha, WI). Briefly, the respiratory signals from the RPM hardware are 
recorded using infrared-reflecting markers on the patient's thorax during quiet, 
uncoached respiration. The markers are illuminated by infrared-emitting diodes 
surrounding a camera, and the motion of these markers is captured by the camera at 
a frequency of 25 frames per second. A respiratory signal is recorded in 
synchronization with the X-ray ‘ON’ signal from the CT scanner. Our current 4D 
protocol for lung tumors uses the 8-slice mode of the CT scanner with a slice 
thickness of 2.5 mm, obtained during quiet respiration. The 4D data sets are sorted 
out for ten phase bins within the respiratory cycle using an Advantage 4DCT 
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application running on an Advantage Workstation 4.1. The volumetric datasets that 
represent 10 different phases of respiration (bins) were used for further analysis. 
 
 
 
Table 1.  Tumor and treatment characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
             
 
 
 
 
 
 
                
                OTT = overall treatment time
Tumor TNM-stage 
Fraction size 
(Gy) 
Total dose 
(Gy) 
OTT (weeks) 
1 T2N0M0 7.5 60 2 
2 T2N0M0 7.5 60 2 
3 T1N0M0 7.5 60 2 
4 T2N0M0 7.5 60 2 
5 T2N0M0 7.5 60 2 
6 T2N0M0 20 60 3 
7 T1N0M0 20 60 3 
8 T1N0M0 20 60 3 
9 T2N0M0 20 60 3 
10 T1N0M0 20 60 3 
11 T1N0M0 20 60 3 
12 T1N0M0 20 60 3 
13 T2N0M0 20 60 3 
14 T1N0M0 20 60 3 
15 T1N0M0 20 60 3 
16 T1N0M0 20 60 3 
17 T1N0M0 20 60 3 
18 T1N0M0 20 60 3 
19 T1N0M0 20 60 3 
20 T1N0M0 20 60 3 
21 T1N0M0 20 60 3 
22 T1N0M0 20 60 3 
23 T1N0M0 20 60 3 
24 T2N0M0 20 60 3 
25 T1N0M0 20 60 3 
26 T2N0M0 20 60 3 
27 T2N0M0 12 60 5 
28 T2N0M0 12 60 5 
29 T1N0M0 12 60 5 
30 T1N0M0 12 60 5 
31 T2N0M0 12 60 5 
32 T1N0M0 12 60 5 
33 T1N0M0 12 60 5 
34 T2N0M0 12 60 5 
35 T1N0M0 12 60 5 
36 T2N0M0 12 60 5 
37 T1N0M0 12 60 5 
38 T1N0M0 12 60 5 
39 T2N0M0 12 60 5 
40 T2N0M0 12 60 5 
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Table 2.Fractionation schemes used at the VU University medical center 
 
 
 
Generating target volumes 
All CT data sets (i.e. six MSCT scans or ten bins from the 4DCT scan) were imported 
into the BrainLab stereotactic radiotherapy planning system (Brainscan ver. 5.2). Co-
registration of CT scans was performed using the automated matching software of this 
planning system, and the results were checked visually by contouring spinal vertebra 
adjacent to the tumor, which was then automatically projected onto each co-
registered CT scan. Gross tumor volumes (GTVs) were contoured in each of the scans 
using a standardized lung window level setting, and the same clinician contoured all 
scans of a particular patient to minimize contouring variations. Up to ten GTVs were 
obtained per patient, i.e. either six from MSCT scans (GTV6 scans) or ten from the bins 
of a 4DCT scan (GTV4DCT). All contours were automatically projected onto either the 
full range MSCT scan or the first ‘bin’ of the 4DCT set, which were used for the 
subsequent analysis. In accordance with recent American Society of Therapeutic 
Radiology and Oncology guidelines [19], no separate margins for deriving clinical 
target volumes (CTVs) were used. For clinical delivery of SRT, the data from the 
multiple MSCT and 4DCT were used to derive individualized mobility margins for 
treatment planning. ITVs for treatment were defined as the encompassing volumes of 
all GTV6 scans or all GTV4DCT, respectively. 
 
Analysis of time trends 
To study volumetric time trends in GTVs during the course of SRT, the mean GTV 
(derived from 10 GTV4DCT or 6 GTV6 scans) for each fraction of SRT was compared to the 
D0 value. For 25 tumors for which complete 4DCT data were available, an analysis for 
trends in tumor mobility was performed. 3D mobility vectors were derived for each 
stereotactic treatment fraction as follows. Using the Brainscan software, the X, Y and 
Z coordinates of the center of mass of the GTVs derived from each 4DCT bin were 
Scheme Indication 
3 x 20 Gy T1N0 tumours, no or minimal contact with chest wall/mediastinum 
5 x 12 Gy T1N0 and T2N0 tumours with extensive contact with chest wall or mediastinum 
8 x 7.5 Gy “High risk” patients (e.g. proximity to spinal cord or pulmonary artery) 
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established. The maximal 2-dimensional displacement in all three directions was 
determined, and a 3D vector was calculated using the Pythagoras’s algorithm. 
 
Because changes in both GTVs and tumor mobility can influence ITVs, the latter were 
also analyzed for each new scan. A spatial analysis of time trends in ITVs was possible 
in only 36 tumors as a result of patient-setup variations in the remaining 4 patients. 
Interfractional shifts in ITV were studied by projecting the center of mass of each ITV 
onto the co-registered D0 planning scan. This co-registration was performed using 
image-registration software from the BrainLab planning system and a contoured 
vertebra at the level of the tumor. Registrations were visually adjusted when needed 
in the sagittal plane to minimize anterior-posterior rotations. The shifts in ITV were 
derived from the X, Y and Z coordinates of the subsequent ITVs, and 3D shift vectors 
compared with the D0 ITV were calculated for each fraction.  
 
Finally, in tumors in which post-treatment follow-up CT scans at three months or six 
months were available, and evaluable for tumor size (36 and 25 tumors, respectively), 
the residual mass was contoured and compared with the mean GTVs during SRT. 
 
Statistical analysis 
The differences in time in mean GTVs and ITVs were evaluated using a mixed model 
for repeated measures data (PROC MIXED, SAS V8.2, SAS Institute Inc., Cary, NC) 
[20]. The existence of potential time trends was correlated with T-classification (T1 
versus T2 tumors), CT scanning technique (multiple MSCT scans versus 4DCT), and 
number of SRT fractions (three versus five versus eight). For within-subject 
correlations, a spatial (spatial power law) covariance structure was defined. This 
structure assumes that correlations of repeated measures are smaller for observations 
that are further apart in time. There was a small difference in variance between the 
“multiple MSCT” and “4DCT” group. Therefore different variance structures were 
allowed. Time, number of fractions, CT scanning technique and T-classification of the 
tumor were considered fixed parameters. 
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Results 
Time trends in GTVs 
The successive mean GTV of 40 tumors during the course of SRT is shown in Figure 1. 
There was a time-trend towards decreasing GTVs, but this was only statistically 
significant when D0 values were compared to GTVs at 4 weeks after the start of 
treatment (p=0.015). As can be seen in Figure 2a, 11 of 40 tumors showed 
substantial regression during treatment. The observed time trend in GTVs was 
irrespective of T-stage, CT scanning technique, or fraction dose. Although overall the 
GTVs decreased over time, a transient increase in the mean GTV of >10 cc was 
observed in 2 tumors during the first two weeks of SRT. 
 
Follow-up CT scans at 3 and 6 months after SRT were assessable for volumetric 
measurement in 36 and 25 tumors, respectively. In all other cases, the follow up was 
either too short or the residual mass could not be distinguished from radiation-
induced fibrosis. Analysis of these follow-up CT scans revealed that regression of 
stage I NSCLC after SRT is a process that proceeds at least until 6 months after 
treatment (Figure 2b).  
 
 
Figure 1. Absolute volumetric changes in mean GTVs during stereotactic   
  radiotherapy (N=40)  
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Figure 2a. Absolute volumes of GTVs at pre-treatment (   ; N=40), end of SRT 
 SRT (   ; N=40), and at 3 months (   ; N=36), 6 months (   ; N=25) 
 follow-up and 1 year follow-up (   ; N=6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2b. Relative changes in mean GTV during and after stereotactic radiotherapy 
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Time trends in ITVs 
A similar time trend as for the GTVs was observed for the ITVs (Figure 3) with an 
overall decrease during SRT. However, just as for the GTVs, this decrease became 
significant only after 4 weeks (p=0.03). The same two cases that showed an increase 
in GTVs during the first two weeks of treatment also showed an increase in ITVs 
compared with baseline values (Figure 3). 
 
Time trends in tumor mobility 
No significant time trend in 3D mobility vectors could be detected in the 25 tumors 
investigated with 4DCT scans (p-value = 0.29-0.94 for the comparison of week 1-4 
with D0 values). However, as can be seen from Figure 4, there was a substantial intra-
patient variability in 3D mobility vectors between fractions, particularly for tumors 
showing a 3D mobility of more than 10 mm. 
 
 
 
Figure 3. Absolute volumetric changes of ITVs during stereotactic treatment 
(N=40) 
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Figure 4. Tumor mobility vectors during stereotactic treatment (N=25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Time trends in spatial position of the ITV 
With reference to position of the center of mass of the D0 ITV, the mean ITV-shifts in 
week 1 to 4 were 4.0 ± 2.5 mm, 3.8 ± 2.2 mm, 4.0 ± 1.4 mm and 4.6 ± 1.5 mm, 
respectively (Table 3). Of the 36 tumors in which repeat CT scans were available for 
treatment planning, 9/33 (27.3%), 7/27 (25.9%), 4/11 (36.4%) and 3/7 (42.9%) 
showed a 3D ITV shift of >5 mm in weeks 1, 2, 3 and 4 respectively. As can be 
observed from Table 3, this ITV-shift exceeded 10 mm in two cases. 
 
Shifts in the center of mass of ITVs can be caused either by changes in tumor mobility 
or by positional translations of the tumor due to, for example, edema or retractions. 
Therefore, the ITV shifts of week 1 and 2 were correlated with changes in tumor 
mobility vectors during SRT. Changes in tumor mobility did not account for the 
observed ITV shifts during SRT, because the correlation coefficient was 0.19 and -0.07 
for week 2 and 3 compared to D0, respectively. 
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Table 3.      Inter-fractional 3D shift in ITV position during a course of stereotactic 
   radiotherapy 
 
 
 
Discussion 
The accurate definition of a target volume is crucial for the delivery of high-precision 
radiotherapy in lung cancer. For patients with peripheral stage I NSCLC, a single 4DCT 
scan appears to be superior to other approaches [7]. However, changes in tumor 
 3D shift (mm) of isocenter 
Tumor week 2 vs. week 1 week 3 vs. week 1 week 4 vs. week 1 week 5 vs. week 1 
1 1.2 3.7 - - 
2 1.0 0.8 - - 
3 4.5 1.7 - - 
4 7.8 11.0 - - 
5 2.2 2.7 - - 
6 7.7 6.9 - - 
7 3.5 - - - 
8 3.5 - - - 
9 4.8 3.8 - - 
10 3.0 4.9 - - 
11 5.1 - 1.7 - 
12 1.8 3.0 - - 
13 2.4 1.1 5.2 1.5 
14 3.1 5.6 - - 
15 4.0 5.1 - - 
16 - 2.5 - - 
17 2.5 5.4 4.2 5.7 
18 6.1 4.3 6.0 5.0 
19 8.5 4.0 - - 
20 3.4 3.4 - - 
21 1.1 - - - 
22 4.1 - - - 
23 10.9 6.5 - - 
24 4.1 2.5 - - 
25 7.2 4.7 - - 
26 5.6 1.9 - - 
27 7.3 - 5.3 - 
28 1.4 - 4.3 - 
29 - - 2.7 - 
30 3.7 3.7 2.7 4.6 
31 - - 3.0 4.5 
32 1.6 1.4 - - 
33 2.0 5.3 5.2 6.2 
34 3.1 2.2 - - 
35 0.6 1.5 - - 
36 4.3 3.3 3.8 4.5 
Mean 3D shift 4.0 3.8 4.0 4.6 
Standard 
Deviation 
2.5 2.2 1.4 1.5 
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volume or mobility arising during the course of treatment may make it necessary to 
adjust a treatment plan to maintain target coverage, while ensuring that critical 
normal organs continue to be spared. 
 
SRT is characterized by both steep dose gradients and a limited number of fractions, 
thereby increasing the impact of any intra- or inter-fractional changes in anatomy. 
Most reports on SRT for lung cancer have used an overall treatment time of 1-2 
weeks, with treatment planning performed only once before the first fraction [10-15]. 
The overall treatment time of our patients extended to a maximum of 5 weeks. 
Because patient-specific margins were used to account for tumor mobility, we opted 
to redefine the ITV prior to each fraction of the common 3 and 5 fraction scheme. 
 
Tumor regression during the course of conventional radiotherapy has been reported 
for NSCLC [8], cervical carcinoma [21, 22], and head-and-neck cancer [23]. The 
latter study reported changes in external contour, shape, and location of the target 
volume and critical structures during radiotherapy for head and neck cancer, 
indicating that periodic adjustment of treatment plans is needed to account for such 
time trends when techniques such as IMRT are delivered. In contrast, no time trends 
were observed for the prostate or seminal vesicles when 3 additional CT scans were 
performed during conventional radiotherapy in 50 patients [24]. An analysis of 
electronic portal images in lung cancer patients reported that it took on average 4.5 
weeks from the start of conventional radiotherapy before ‘tumor size’ decreased to 
below 80% of the original size [8]. A slow regression rate was also observed in 22 
patients with NSCLC who were treated with either radiotherapy alone or chemo-
radiotherapy. In the latter study, the time required for maximum tumor regression 
ranged from 5-11 months [9]. Our study confirmed the finding of a slow regression of 
lung tumors, because significant decreases in target volumes were only observed after 
the fourth week of SRT, with most regression evident in the first three months after 
completion of SRT.  
 
An initial increase in tumor volumes after stereotactic radiotherapy or radiosurgery 
has been reported for intracranial lesions such as brain metastases [25, 26], 
vestibular schwannomas [27, 28], craniopharyngiomas [29], gliomas [30], and 
pituitary adenomas [31]. The present analysis of planning CT scans performed during 
SRT with similar fraction sizes revealed an increase in GTVs and ITVs of 10 cc or more 
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in the second week of treatment in only 5% of stage I tumors. It can be concluded 
from these data that volumetric changes do not play an important role in inter-
fractional variations in target volumes during SRT for lung cancer. 
 
A study on spirometry assisted breath-hold CT scans at the end of high-dose 
conventionally fractionated radiotherapy reported significant changes in both tumor 
position at end-expiration and mobility [32]. In our study, a change in 3D mobility 
vectors with respect to baseline values of at least 3 mm was observed in 20% of 
tumors. This finding was observed in tumors that were more mobile, and may be 
related to the variations in respiratory amplitude during quiet uncoached respiration. 
The latter is the subject of ongoing analysis and may underscore the importance of 
performing respiratory coaching during both 4DCT scanning and treatment delivery. 
 
An important finding of this study was the occurrence of substantial inter-fractional 
shifts of ITVs during the 3- to 5-week course of SRT. These shifts could be 
demonstrated as early as one week from the start of SRT and did not correlate with 
the observed alterations of tumor mobility. These shifts, which may be caused by 
radiation-induced changes in the surrounding normal tissues [33, 34], illustrate the 
importance of repeat imaging during SRT for lung cancer. 
 
In conclusion, clinically significant positional time trends in target volumes can occur 
during a course of SRT for stage I NSCLC. A failure to account for such changes, e.g. 
by repeat CT-planning or verification using on-board volumetric imaging, can lead to 
inadequate target coverage. 
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Abstract 
Background: Respiration-gated radiotherapy can permit the irradiation of smaller 
target volumes. 4DCT scans performed for routine treatment were retrospectively 
analyzed to establish the benefits of gating in stage III non-small cell lung cancer 
(NSCLC). 
Methods and Materials: Gross tumor volumes (GTVs) were contoured in all 10 
respiratory phases of a 4DCT scan in 15 patients with stage III NSCLC. Treatment 
planning was performed using different planning target volumes (PTVs), namely: (i) 
PTVroutine, derived from a single GTV plus ‘conventional’ margins; (ii) PTVall phases 
incorporating all 3D mobility captured by the 4DCT; (iii) PTVgating, incorporating 
residual 3D mobility in 3-4 phases at end-expiration. Mixed effect models were 
constructed in order to estimate the reductions in risk of lung toxicity for the different 
PTVs. 
Results: Individual GTVs ranged from 41.5 - 235.0 cm3. With patient-specific mobility 
data (PTVall phases), smaller PTVs were derived than when ‘standard’ conventional 
margins were used (p<0.001). The average residual 3D tumor mobility within the 
gating window was 4.0 ± 3.5 mm, which was 5.5 mm less than non-gated tumor 
mobility (p<0.001). The reductions in mean lung dose were 9.7% and 4.9%, 
respectively, for PTVall phases versus PTVroutine, and PTVgating versus PTVall phases. The 
corresponding reductions in V20 were 9.8% and 7.0%, respectively. Dosimetric gains 
were smaller for primary tumors of the upper lobe versus other locations (p=0.02). 
Respiratory gating also reduced the risks of radiation-induced esophagitis. 
Conclusion: Respiration-gated radiotherapy can reduce the risk of pulmonary toxicity 
but the benefits are particularly evident for tumors of the middle and lower lobes.
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Background 
As lung tumors can show significant respiration-induced motion [1, 2], sufficient 
margins have to be added to account for target mobility in radiotherapy planning [3]. 
For stage I non-small cell lung cancer (NSCLC), commonly used ‘population-based’ 
margins result in unnecessary irradiation of significant amounts of normal tissue [2, 
4], thereby increasing the risk of toxicity. For stage III NSCLC, local control after 
radiotherapy is poor [5, 6], and both radiation dose-escalation and concurrent chemo-
radiotherapy schemes have been used in an attempt to improve local control. 
However, such approaches can increase late radiation-induced toxicity [7-11], and 
reductions in treated volumes may help in reducing toxicity. 
 
Respiration-correlated (or 4D) CT scans permit an individualized assessment of tumor 
mobility [12]. Respiratory gating enables smaller target volumes to be used as 
treatment delivery is restricted to predetermined phases of respiration, during which 
tumor mobility is relatively limited. However, planning and delivery of gated 
radiotherapy requires reliable data on intra- and inter-fractional tumor mobility. In 
stage I NSCLC, individualized planning target volumes (PTVs) that incorporated all 
tumor mobility or the residual mobility in three end-expiratory phases allowed for 
mean PTV reductions of 48.2% and 33.3%, respectively, relative to standard margins 
[2]. The magnitude of benefit that can be achieved with gating in stage I tumors was 
found to correlate with the extent of mobility. 
A recent study in patients with stage III NSCLC reported that limited decreases in lung 
doses could be achieved with gating, but only if GTVs did not exceed 100-150 cm3 
[13]. However, tumor mobility in this study was derived from breath-hold CT scans at 
full inspiration and tidal end-expiration. A more realistic analysis requires knowledge 
of mobility in all phases of quiet respiration, i.e. 4DCT data. We retrospectively 
analyzed 4D datasets in order to determine the geometric and dosimetric benefits of 
respiration-gated radiotherapy in stage III NSCLC. 
 
Methods 
The 4DCT scans of 15 consecutive patients with stage III NSCLC, who were treated 
with conventionally fractionated involved-field radiotherapy at the VU University 
medical center, were retrospectively analyzed. The primary tumors were located in 
the upper (n=9), middle (n=2) and lower lobe (n=4), respectively. Patient 
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characteristics are summarized in Table 1. All patients had at least one metastatic N2-
3 lymph node, and nodal locations were described according to Mountain et al. [14]. 
 
 
 
 
Table 1. Patient characteristics 
      
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lymph node locations are according to Mountain et al. [14] 
 
 
 
4DCT scanning procedure 
Patients were immobilized in the supine position, with the arms positioned above the 
head on an adjustable arm support and a knee rest device was used (Posirest-2 and 
Kneefix cushion device, Sinmed, Reeuwijk, The Netherlands). A 4DCT thoracic scan 
was performed during uncoached quiet respiration on a 16 slice CT scanner. The 
Respiratory Position Management gating hardware (Varian Medical Systems, Palo Alto, 
CA) was used for recording the breathing pattern. A lightweight block containing two 
reflective markers is placed on the upper abdomen, typically halfway between the 
xiphoid and umbilicus, and infrared light from an illuminator is reflected from the 
markers, and captured by a camera. 
 
Our 4DCT protocol for scanning lung tumors has been reported in detail previously 
[12]. Briefly, 8 contiguous slices of 2.5 mm are generated for a 2 cm total longitudinal 
coverage per gantry rotation with the scanner operated in axial cine mode. Other 
Patient 
TNM-
stage 
Primary tumor 
location 
Lymph node 
locations 
GTV 
(cm3) 
1 T2N2M0 Right upper lobe 2R, 4R 101.4 
2 T3N2M0 Left upper lobe 4L 231.6 
3 T2N3M0 Right upper lobe 4R, 4L 63.6 
4 T2N2M0 Right lower lobe 7 77.9 
5 T3N3M0 Right upper lobe 4R, 4L 174.7 
6 T2N2M0 Right lower lobe 4R 99.1 
7 T3N2M0 Right lower lobe 4R, 7 61.7 
8 T2N2M0 Right upper lobe 4R 74.8 
9 T1N3M0 Right middle lobe 4R, 4L 71.8 
10 T2N2M0 Left lower lobe 4L, 7 180.9 
11 T4N3M0 Right upper lobe 4L 154.6 
12 T2N2M0 Left upper lobe 2L, 4L 41.5 
13 T2N3M0 Right upper lobe 2R, 4R, 4L 84.2 
14 T3N2M0 Left upper lobe 4L 235.0 
15 T3N2M0 Right middle lobe 2R, 4R, 7 164.3 
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scanning parameters include 140 KV, 95 mA and tube rotation set closest to 1/10 of 
the average breathing cycle time to allow high temporal and spatial resolution. With 
the scanner couch in static mode, data is acquired for at least the duration of one full 
respiratory cycle, after which the couch advances to the next position. Data 
acquisition ceases during the couch movement, and a full 4DCT scanning procedure of 
the thorax generally takes about 90 seconds. The radiation exposure from the 4DCT 
acquisition is about 52.7 mGy in CTDIvol when the patients’ breathing cycle is 4 sec, 
which is about 6 times the dose of our single conventional helical CT scan procedure. 
Retrospective sorting of the images into spatio-temporally coherent volumes is 
performed using the Advantage 4D software (GE Medical Systems, Waukesha, WI). 
Each reconstructed image is assigned to a specific respiratory phase (or ‘bin’) based 
on the temporal correlation between surface motion and data acquisition, and 10 
respiratory phases are generated. The actual clinical treatment of these patients was 
based upon non-gated treatment delivery to a PTV that incorporated mobility seen in 
all phases of respiration (PTVall phases). 
 
In this retrospective analysis, the bins representing all 10 phases of respiration were 
imported into the Eclipse radiotherapy planning system (Eclipse version 6.5, Varian 
Medical Systems, Palo Alto, CA). All ten 3D data sets derived from a 4DCT scan 
shared DICOM coordinates, which simplified image registration of the data sets using 
the “shared DICOM coordinates” option. After image registration, the position of a 
vertebra at the level of the primary tumor was checked to ensure that no patient 
movement had occurred during the 4DCT acquisition procedure. 
 
Defining the ‘gating- window’ 
As gating will prolong treatment delivery, it is common to use a ‘gate’ that allows a 
duty cycle of at least between 20-40% of respiration [15]. In order to identify the 
gate, all ten 4DCT bins were imported into the ‘4D Review’ application in the 
Advantage workstation where 3 or 4 consecutive ‘gating bins’ in expiration were 
simultaneously viewed in axial, frontal and sagittal reconstructions. A ‘gating window’ 
was identified at end-expiration in which mobility of the primary tumor and/or hilus 
was minimal. The use of larger gating windows improve the efficiency of treatment 
delivery, and a total of 4 phases were selected in 4 patients as review of the 4DCT 
movies suggested limited mobility of the primary tumor within in these ‘gates’. 
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Deriving target volumes and contouring critical structures 
Gross tumor volumes (GTVs) were contoured in each of the 10 phases of a 4DCT 
using standardized lung and mediastinal window level settings by one clinician in 
order to minimize contouring variations. The use of involved-field radiotherapy is 
standard practice at our center for the treatment of stage III NSCLC [16], and the 
GTV included the primary tumor, ipsilateral hilus, lymph nodes with a short axis 
diameter of 1.0 cm or greater and/or FDG-PET positive lymph nodes. All contours 
were automatically projected onto the second ‘bin’ in the middle of the gating window. 
Similarly, the spinal cord and esophagus were also contoured in this specific ‘gating 
bin’. In six patients, the primary tumor and the hilus were contoured as a single entity 
as the two structures were adjacent to each other. For all 15 patients, three PTVs 
were generated: 
(i) PTVroutine, derived from a phase at the center of the ‘gating window’, i.e. from a 
single component CT scan. An isotropic margin of 1.5 cm (but 2.0 cm for cranial and 
caudal margins in lower lobe tumors) was added to the GTV in order to account for 
microscopic extension, mobility and set-up inaccuracies; 
(ii) PTVall phases, which consisted of the volume encompassing all ten GTVs (i.e. all 
respiration-induced mobility), plus an isotropic margin of 1.0 cm for microscopic 
extension and set-up inaccuracies; 
(iii) PTVgating, consisting of the volume encompassing 3-4 GTVs in the gating window, 
plus an isotropic margin of 1.0 cm for microscopic extension and set-up inaccuracies. 
 
Analysis of target mobility 
A ‘bounding box’ technique was used to assess the mobility of GTVs, as was 
previously reported [17]. Briefly, the approach involves fitting a rectangular box to 
each target volume, and changes in the position of a moving target in the X-, Y- and 
Z-axes are derived from the corresponding sides of the box. The overall 3D 
displacement of each GTV was derived using Pythagoras’s algorithm. The following 
analyses were performed: (i) mobility of individual GTVs, derived from displacement 
of a single GTV (GTVsingle phase) within GTV all phases, (ii) the reduction in mobility 
achieved with the use of respiratory gating, derived from calculating the displacement 
of the GTVgating within GTVall phases, and (iii) residual GTV mobility within gating 
windows, derived from displacement of the GTVsingle phase within GTVgating. 
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Treatment planning and dosimetric analysis 
Treatment planning was performed on each PTVroutine, PTVall phases and PTVgating, all of 
which were projected onto a single end-expiratory CT set. The study patients were 
treated using two different fractionation schemes, namely 60 Gy in 30 fractions and 
46 Gy in 23 fractions. The latter was a dose used for pre-operative concurrent chemo-
radiotherapy. For both schemes, the PTVs received at least 95% of the prescribed 
dose, and a dose maximum of 107% of the prescribed dose was accepted unless a 
higher dose maximum was located within the PTV. The V20 values had to be 35% or 
less, with a dose to the spinal cord of 50 Gy or less. An initial treatment plan was 
derived for PTVroutine, and treatment plans for PTVall phases and PTVgating were then 
derived by shrinking the fields of the initial plan, without other changes to the beam 
setup. The target conformity indices (CI), i.e. ratio of the target volume to volume 
treated to the 95% dose, of all three plans for each patient were derived to ensure 
that plan coverage was comparable. Dose–volume histograms (DVH) were computed 
for the total lung minus the volume of PTVgating in order to generate a reference lung 
volume that was copied to each treatment plan. The maximum spinal cord dose and 
predictors of lung toxicity, the V20 and mean lung dose (MLD) [18], were evaluated for 
each plan. The length of the esophageal circumference encompassed by the 40 Gy 
and 50 Gy isodose was obtained by visually scrolling through axial CT slices. 
 
Statistical analysis 
The differences between the three PTVs and the reduction in GTV mobility achieved 
with gating were evaluated using the Hodges-Lehman non-parametric test. The 
existence of a correlation between the reduction in GTV mobility with respiratory 
gating and the dosimetric gains achieved, were evaluated using the Spearman’s 
nonparametric correlation test. In addition, the dosimetric data were analyzed for 
differences according to tumor stage and tumor location (upper vs. non-upper lobe). 
All statistical analyses were conducted using the Cytel Studio’s StatXact-6 software 
(Version 6.2.0). Finally, mixed effect models were constructed (SAS version 8.02 and 
S-plus version 6.2) in order to estimate the general dosimetric gains that can be 
achieved (PTVroutine vs. PTVall phases; PTVroutine vs. PTVgating; PTVall phases vs. PTVgating) on the 
V20 and MLD, as well as on critical structures (esophagus and spinal cord). 
 
Chapter 6 
 
 86 
Results 
Volumetric comparison of PTVs 
The individual GTVs ranged from 41.52 cm3 to 235.04 cm3, and six GTVs were larger 
than 150 cm3 (Table 1). The PTVroutine was the largest volume for all patients (Figure 
1). Use of individualized margins led to significantly smaller volumes (PTVall phases) than 
with the use of standard margins (p<0.001). The same was observed for PTVgating 
versus PTVall phases (p<0.001). 
 
 
 
 
 
Figure 1. Absolute volumes of PTVroutine (  ), PTVall phases (   ) and PTVgating (  ) 
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Table 2. GTVs and GTV mobility 
    # gating-window incorporated four successive phase bins 
     * mainly due to residual nodal mobility in the mediastinum 
 
 
Treatment planning 
Treatment was planned to a dose of 60 Gy for 11 of the 15 patients. The other four 
had lesions of the upper lobe that extended to the contralateral mediastinum, and all 
these patients underwent pre-operative chemo-radiotherapy to 46 Gy. A similar target 
conformity index (CI) was achieved for plans based on the 3 specified PTV definitions 
(data not shown). 
 
Reduction in the risk of pulmonary toxicity with gating was assessed using dedicated 
statistical models for all patients (n=15) on mean lung dose (MLD) and in 14 patients 
with respect to the volume of lungs receiving at least 20 Gy (V20). One patient was 
excluded from the V20 model as the V20 values of the plans did not meet the V20 
inclusion criteria, i.e. V20 (routine) > V20 (all phases) > V20 (gating). In this patient 
with a right lower lobe tumor, the V20 (all phases) was larger than the V20 (routine), 
which was the result of substantial lateral mobility of the mediastinal lymph nodes. 
Nevertheless, the PTVall phases plan did meet the inclusion criteria used in the MLD 
model, i.e. MLD (routine) > MLD (all phases) > MLD (gating). The mixed effect model 
showed that the MLD was reduced by 9.7%, 4.9% and 14.2%, respectively, for    
Patient 
GTVall phases 
(cm3) 
GTVgating 
(cm3) 
Ungated GTV 
mobility (mm) 
Residual GTV 
mobility (mm) 
1 126.9 104.1 5.6 2.2 
2 247.4 239.0 1.0 0.0# 
3 76.3 68.1 11.2 5.8 
4 132.3 90.6 17.3 6.4 
5 201.0 183.4 8.2 3.2# 
6 128.6 112.5 22.6 14.0#* 
7 98.4 66.8 18.2 5.9 
8 112.7 81.9 10.9 2.0 
9 109.8 79.8 8.4 1.4 
10 216.3 193.2 3.0 2.0 
11 199.8 162.5 8.7 4.6 
12 49.7 44.0 1.0 1.0# 
13 97.7 89.0 8.4 6.4 
14 254.0 239.3 4.6 1.0 
15 240.7 193.3 12.6 3.6 
Mean 152.8 129.8 9.4 4.0 
SD 67.1 65.5 6.3 3.5 
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PTVall phases versus PTVroutine, PTVgating versus PTVall phases and PTVgating versus PTVroutine. 
The corresponding figures for the V20 were 9.8%, 7.0% and 16.2% (Tables 3-4). 
Upper lobe tumors showed a significantly lower dosimetric gain than tumors located in 
other lobes (p=0.02). When the analysis was restricted to lower and middle lobe 
tumors, the corresponding figures for V20 reduction were 7.2%, 10.1% and 16.5%, 
and for reduction in MLD 9.9%, 6.4% and 15.7%, respectively. Tumor stage had no 
significant influence on the dosimetric improvements achieved with respiratory gating. 
 
As could be expected, a strong correlation was observed between the reduction in PTV 
observed with respiratory gating and the reduction in GTV mobility (Spearman’s Non-
parametric correlation test S=0.78, linear regression coefficient=4.3 (p<0.001)). In 
addition, a correlation could be demonstrated between the reduction in PTV with 
gating and reductions in both in V20 and MLD values (Figure 2a-b). 
 
 
 Table 3. Reduction in mean lung dose (Gy) using different PTV definitions 
 
Mean lung 
dose (Gy) 
Absolute (Gy) and relative (%) 
reduction in mean lung dose 
Patient PTVroutine 
PTVall phases 
vs. 
 PTVroutine 
PTVgating 
vs. 
 PTVroutine 
PTVgating 
vs. 
PTVall phases 
1 25.2 2.7 (10.7%) 3.6 (14.3%) 0.9 (4.0%) 
2 20.6 1.6 (7.8%) 2.4 (11.7%) 0.8 (4.2%) 
3 18.9 1.6 (8.5%) 2.2 (11.6%) 0.6 (3.5%) 
4 23.0 1.3 (5.7%) 3.0 (13.0%) 1.7 (7.8%) 
5 12.8 1.1 (8.6%) 1.5 (11.7%) 0.3 (2.6%) 
6 18.7 1.7 (9.1%) 2.5 (13.4%) 0.8 (4.7%) 
7 23.1 3.1 (13.4%) 4.2 (18.2%) 1.1 (5.5%) 
8 10.4 0.7 (6.7%) 0.7 (6.7%) 0.0 (0.0%) 
9 19.3 1.1 (5.7%) 2.7 (14.0%) 1.6 (8.8%) 
10 20.2 3.0 (14.9%) 3.8 (18.8%) 0.8 (4.7%) 
11 17.2 1.0 (5.8%) 2.1 (12.2%) 1.1 (6.8%) 
12 19.5 3.2 (16.4%) 3.3 (16.9%) 0.1 (0.6%) 
13 14.2 1.2 (8.5%) 2.4 (16.9%) 1.2 (9.3%) 
14 15.7 2.1 (13.4%) 2.6 (16.6%) 0.5 (3.7%) 
15 27.8 3.0 (10.8%) 4.7 (16.9%) 1.7 (6.9%) 
Mean 19.1 1.9 (9.7%) 2.8 (14.2%) 0.9 (4.9%) 
SD 4.6 0.9 (3.4%) 1.0 (3.2%) 0.5 (2.7%) 
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Table 4. Reduction in V20 (%) using different PTV definitions 
 V20 (%) 
Absolute V20 (%) and relative (%) reduction 
in V20 
Patient PTVroutine 
PTVall phases 
vs. 
PTVroutine 
PTVgating 
vs. 
 PTVroutine 
PTVgating 
vs. 
PTVall phases 
1 38.0 4.1 (10.8%) 5.1 (13.4%) 1.0 (2.9%) 
2 27.1 2.2 (8.1%) 3.5 (12.9%) 1.3 (5.2%) 
3 29.0 2.0 (6.9%) 2.8 (9.7%) 0.8 (3.0%) 
4 31.0 3.8 (12.3%) 6.7 (21.6%) 2.9 (10.7%) 
5 26.1 2.2 (8.4%) 2.9 (11.1%) 0.7 (2.9%) 
6 28.9 -1.5 (-5.2%) 0.1 (0.3%) 1.6 (5.3%) 
7 26.2 0.9 (3.4%) 4.3 (16.4%) 3.4 (13.4%) 
8 20.5 3.7 (18.0%) 4.4 (21.5%) 0.7 (4.2%) 
9 28.2 1.7 (6.0%) 4.8 (17.0%) 3.1 (11.7%) 
10 27.5 4.2 (15.3%) 6.5 (23.6%) 2.3 (9.9%) 
11 27.6 2.4 (8.7%) 4.9 (17.8%) 2.5 (9.9%) 
12 25.5 4.4 (17.3%) 4.9 (19.2%) 0.5 (2.4%) 
13 28.8 2.9 (10.1%) 6.0 (20.8%) 3.1 (12.0%) 
14 23.9 3.7 (15.5%) 4.2 (17.6%) 0.5 (2.5%) 
15 42.8 5.0 (11.7%) 8.6 (20.1%) 3.6 (9.5%) 
Mean 28.7 2.8 (9.8%) 4.6 (16.2%) 1.9 (7.0%) 
SD 5.4 1.7 (5.9%) 2.0 (6.0%) 1.2 (4.1) 
 
 
 
Esophageal and spinal dose parameters 
With the use of involved-field radiotherapy, only 11 patients received an esophageal 
circumference dose of at least 40 Gy. The mean circumferential length receiving a 
dose of 40 Gy was 6.8 ± 2.3 cm for PTVroutine. Use of PTVall phases reduced this value by 
a mean of 0.8 cm, and the reduction with PTVgating was 1.2 cm, both proven significant 
(Satterthwaite approximation for the denominator degrees of freedom used to give 
accurate F approximations). A circumferential dose of 50 Gy was seen in 8 patients, 
and the mean esophageal circumference receiving 50 Gy was 5.3 ± 2.0 for PTVroutine. 
Use of PTVall phases and PTVgating reduced this value by a mean of 1.8 and and 2.3 cm, 
respectively (p<0.001, Page T: k-tuple non-parametric exact test for grouped data). 
 
The maximum spinal cord dose was 44.7 ± 7.4 Gy for involved-field treatment plans 
generated for PTVroutine, and non-significant reductions to 43.7 ± 7.7 Gy and 42.8 ± 
8.8 Gy were seen for plans based on PTVall phases and PTVgating.  
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Figure 2a-b. Dosimetric correlation between (a) PTV reduction and V20 reduction,
 and (b) PTV reduction and MLD reduction 
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Discussion 
Attempts to improve local control in stage III NSCLC have been confounded by an 
increased incidence of treatment-related toxicity, including unexpected late toxicities 
such as symptomatic bronchial stenosis, mediastinal fibrosis and stenosis of the 
pulmonary artery [9, 11]. The reporting of significant lung tumor motion has led to 
large margins being added to the clinical target volume to ensure adequate dose 
coverage. As such, respiration-gated radiotherapy is an approach that can reduce the 
volume of irradiated normal tissue. 
 
This study in 15 consecutive patients with stage III NSCLC highlights the volumetric 
and dosimetric gains that can be achieved using individualized PTVs that incorporate 
all tumor motion and also respiration-gated PTVs in expiratory phases. Of note is the 
finding that significant gains are attained simply by using individualized 4D mobility 
margins (i.e. PTVall phases) instead of PTVs based upon standard margins of 1.5 cm. The 
additional reductions in lung toxicity parameters achieved with respiratory gating were 
generally modest, but strongly correlated with the reduction in tumor mobility 
achieved with gating. Careful patient selection appears required to establish the 
optimal benefit. 
 
Just as for stage I NSCLC [2], the larger PTVroutine did not achieve coverage of all 
mobility in 7 of the 15 patients with tumors in upper- (n=2), middle- (n=2), and lower 
lobes (n=3). For the upper lobe tumors, the mobility of mediastinal lymph nodes 
appeared to be inadequately incorporated using standard margins; for the middle and 
lower lobe tumors this was the case for either the subcarinal nodes (n=2), mediastinal 
lymph nodes (n=3) or the primary tumor (n=2). 
 
This analysis of 4DCT data revealed that reductions in both V20 and MLD can be 
achieved even when GTVs exceed 150 cm3, but that this was restricted to tumors 
located in middle and lower lobes. For the latter, the mean reduction in V20 was 10.1 
± 2.7% for PTVgating relative to PTVall phases. In contrast, recent reports suggested that 
dosimetric benefits for gated radiotherapy were restricted to patients whose GTVs 
were 150 cm3 or less, and which also exhibited significant mobility [13]. The mean 
mobility in our 15 patients (9.4 ± 6.3 mm) was similar to that of the 20 patients in 
the abovementioned report (9.4 ± 4.1 mm). 
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The potential benefits of respiratory gating must be viewed in the light of the residual 
uncertainties during gated delivery, for example the correlation between the PTV and 
external respiratory surrogates [19]. As changes in target volumes for lung cancer 
have been observed during both stereotactic radiotherapy [20] and conventionally 
fractionated radiotherapy [21], the relationship between external markers and the 
PTV may have to be re-established during treatment. Ongoing developments in 
volumetric imaging at the treatment unit may increase the accuracy of respiration-
gated radiotherapy. 
 
Another approach explored for reducing toxicity is intensity-modulated radiotherapy 
(IMRT). A planning study comparing IMRT and 3D conformal radiotherapy in 41 
patients with locally-advanced stage NSCLC reported a median reduction in V20 of 
10% and a reduction in MLD of ≥2 Gy [22]. However, 4D treatment planning for 
conformal radiotherapy and IMRT is in its infancy [23]. 
 
A limitation of our study is the fact that the esophagus was contoured in only one 
phase of respiration position. Recent data suggests that respiration-induced mobility 
of the lower esophagus can occur [24], which can confound our conclusions about the 
dosimetric impact of gated delivery. 
 
Conclusions 
Our analysis of 4DCT data indicates that individualized 4DCT-based PTVs ensure 
optimal target coverage with minimal irradiation of normal tissues in patients with 
stage III NSCLC. Respiration-gated radiotherapy can further reduce the risk of 
pulmonary toxicity, particularly for tumors located in the middle and lower lobes. 
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Respiration-induced tumor mobility is an important source of geometric uncertainty in 
both radiotherapy planning and delivery for lung cancer. Furthermore, it has been 
reported that mobility of lung tumors is unpredictable, as no clear correlation exists 
between the anatomical location of the lung tumor and the amount of mobility [1].  
 
Radiotherapy planning is commonly based on a single rapid planning CT scan that is 
acquired during free breathing. It has, however, been demonstrated that such a scan 
of a moving tumor can lead to distortions in shape and deviations in spatial position of 
the target volume [2]. A single conventional CT scan represents a random position of 
the tumor during the respiratory cycle. As a mobile tumor or organ may not be at its 
mean position at the time of imaging, the dose calculated in such a static patient 
model is unlikely to represent the actual dose delivery during treatment. This can 
result in systematic errors in target definition, which are important as they influence 
all treatment fractions, thereby causing a ‘change’ in the dose distribution with 
respect to the target volume. Therefore, the use of a single rapid CT scan for target 
definition is questionable. 
 
In order to improve target definition, the International Commission on Radiation Units 
and Measurements has recommended the use of an internal target volume (ITV) that 
includes all internal motion of the clinical target volume (CTV) [3]. In order to 
generate a planning target volume (PTV) most departments use population-based 
CTV-PTV margins for 3-dimensional conformal radiotherapy (3DCRT), and also even 
for stereotactic radiotherapy (SRT) in stage I non-small cell lung cancer (NSCLC). 
Several approaches have been developed to incorporate individualized ITVs into 
treatment planning, including multiple planning CT scans [4], fusion of target volumes 
generated from ‘two-phase’ CT scans [5] and slow CT scanning [6].  
 
Recently, a more sophisticated approach, respiration-correlated (or 4D) CT scanning, 
has become available, which enables changes in position and shape of a patient’s 
internal anatomy to be quantified as a function of the respiratory cycle. 4DCT requires 
multiple CT slices to be performed for at least the duration of one respiratory cycle 
(‘oversampling’) at each predefined table position, while the respiratory signal is 
recorded simultaneously using a respiratory monitoring system. Usually, all images 
from a 4DCT scan are evenly distributed over 10 bins, each corresponding to the 
phase of the respiratory cycle in which the image was acquired. The complete set of 
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bins accumulated over a respiratory cycle constitutes a 4D dataset. Motion artefacts 
are significantly reduced in the 4D datasets, compared to conventional CT scans.  
 
Optimal target definition is a key requirement for radiotherapy. However, this is 
especially important for high-precision radiotherapy techniques, such as 
hypofractionated SRT, respiratory gating, and intensity modulated radiotherapy 
(IMRT). Several phase I/II studies recently reported local control rates of 80-90% 
with hypofractionated SRT for patients with inoperable stage I NSCLC [7-11]. In view 
of the high radiation doses (>100 Gy) and the steep dose gradient characteristic of 
SRT, this requires optimal target definition to ensure accurate dose delivery. As 
previously mentioned, most reports on SRT [7-9] and 3DCRT [12] in stage I lung 
cancer use population-based CTV-PTV margins to deal with internal tumor mobility. 
Our analysis demonstrates that the use of a single 4DCT scan captures more 
respiration-induced motion in highly mobile tumors, compared to population-based 
margins [Chapter 2, this thesis]. The latter leads to a diminished dose delivery to the 
target volume in these cases, while more healthy tissue is irradiated, indicating that 
population-based margins are inappropriate for ITV generation in stage I NSCLC. 
Furthermore, we showed that a single 4DCT scan is equal to, or better than, using 6 
rapid CT scans for ITV generation, especially in highly mobile tumors [Chapter 2, this 
thesis]. 
 
The clinical implementation of 4DCT scanning leads to a huge increase of patient data 
that has to be used for target definition. Usually, ten respiration-correlated 3D 
datasets are derived from a single 4D dataset, each representing the patient’s 
anatomy during a single respiratory phase. Without practical solutions this requires 
contouring of the gross tumor volume (GTV) in 10 respiratory phases, which is a 
major drawback to the routine clinical use of 4DCT scans in lung cancer. This 
underscores the need for solutions that result in a more efficient clinical use of 4DCT 
scans. One method is the use of ‘maximum intensity projections’ (MIP). Our analysis 
regarding the use of this post-processing tool reveals that it enables reliable 
generation of individualized ITVs from 4D datasets, thereby establishing a significant 
decrease in contouring time [Chapter 3, this thesis]. However, this tool is unable to 
visualize the movement of mediastinal lymph nodes that are present in stage III lung 
tumors. Furthermore, caution is needed with tumors that are located adjacent to high-
intensity thoracic structures such as the heart, the diaphragm and the thoracic wall, 
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as we showed that MIP images may fail to visualize the entire ITV, due to the overlap 
with these high-density organs. The use of MIPs has the ‘disadvantage’ that it 
represents all spatial positions of a lung tumor during the respiratory cycle, and not 
the time spent at each position. This can be seen as suboptimal use of 4DCT 
information. The use of another post-processing tool, ‘average intensity projection’, 
represents the ‘time-weighted’ location of a tumor. To date, however, no data has 
been published about the use of average intensity projections in target definition and 
treatment planning. Therefore its role remains to be established. 
 
In the same analysis we describe the use of contouring GTVs on the ‘minimum 
intensity projection’ (MinIP) in 4D datasets. The MinIP volume represents the volume 
where tumor tissue is present during the entire breathing cycle.  Engelsman et al. 
reported that the probability of tumor control could be increased by the combination 
of field-size reduction and dose-escalation (i.e. an inward shift of the 95% isodose), 
thus increasing the target dose inhomogeneity [13]. This was performed while 
maintaining an equal mean lung dose (MLD), while respiratory motion was also taken 
into account. A possible explanation for the increased probability of tumor control is 
that an inwards shift of the 95% isodose enables delivery of a higher total dose to the 
volume in which tumor tissue was present during most of the breathing cycle time, 
resulting in a higher percentage of cell kill. However, in order to test this hypothesis, 
tools for efficient 4D data visualization are required. Recently, ‘color intensity 
projections’ were reported to rapidly visualize the percentage of time tumor tissue was 
present in a certain part of the ITV during the breathing cycle [14].  
 
The clinical toxicity of SRT for inoperable stage I NSCLC is limited due to the 
application of involved-field radiotherapy in relatively small tumors and the use of 
small margins. However, recent publications have reported unexpected toxicities such 
as main bronchus stenosis, tracheal necrosis, oesophageal ulceration and pericardial 
effusion [15, 16]. Other potential organs at risk are the spinal cord and the thoracic 
wall. In order to limit the risk of treatment-related toxicity to these organs, 
respiratory gating can be performed. Our analysis of respiration-gated SRT for stage I 
NSCLC indicates that this technique enables reduction of normal tissue irradiation in 
all analyzed patients. However, we also found that the largest volumetric gains are 
obtained with the incorporation of all respiration-induced tumor mobility into the PTV. 
As PTVs in stage I NSCLC are generally small, a considerable volumetric reduction has 
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to be achieved in order to attain a benefit in clinical toxicity. We arbitrarily defined a 
threshold of at least a 50% PTV reduction and found that less than 15% of the 
patients fulfilled these criteria. This indicates that careful selection of patients is 
required. We proposed two simple approaches for this purpose. The first method is 
the use of the ratio between the ITV that is contoured on the MinIP projection to that 
delineated on the MIP image. Our analysis shows that this ratio correlates very well 
with the reduction in ITV that could be achieved with respiratory gating (Chapter 3, 
this thesis). The second approach requires the use of the two extreme GTV positions 
during the respiratory cycle. The ratio of the intersecting and the encompassing 
volume of these GTVs proved to be an excellent predictor for the reduction of the PTV 
with respiration-gated treatment (Chapter 4, this thesis). These two measures both 
were less time-consuming than contouring all ten respiratory bins. In clinical practise, 
however, we do not yet apply respiratory gating in this patient group, mainly because 
gating would result in unacceptable prolongation of the duration of each SRT fraction. 
 
The use of tumor-tracking systems that continuously monitor the tumor position 
would, in theory, yield the largest benefits with respect to patient comfort and 
treatment time, since radiation is delivered throughout the patient’s entire respiratory 
cycle. However, this approach requires the insertion of fiducial markers, which can be 
performed through invasive techniques, such as endobrochial or transthoracic 
placement. With endobrochial placement often only one marker can be placed near 
the tumor [17], while it has been reported that at least 3 markers are needed to 
detect rotational tumor movement [18]. Furthermore, it is questionable whether 
movements of implanted markers reliably track hysteresis, and if their movement 
changes synchronously with the inter-fractional changes in mobility, that we observed 
throughout the treatment [Chapter 5, this thesis]. In addition, the reported risk of 
marker-drop is as high as 14% [19], while other authors suggested that as much as 
25% of the inserted markers could not be detected throughout the treatment [20]. 
Transthoracic marker placement is comparable to a CT-guided biopsy and 
complications such as pneumothorax may occur in up to 46% [21]. This complication 
is potentially fatal for these patients due to their compromised respiratory function.  
 
In our analyses on respiration-gated treatment, all patients were scanned during 
uncoached quiet respiration after a reproducible pattern of respiration was observed. 
However, one should be aware that the amplitude and frequency of the respiratory 
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signal can vary during free breathing, especially in patients with limited pulmonary 
function. It has been reported that respiratory coaching using visual feedback and/or 
audio prompting can increase the gating window [22]. The issue whether respiratory 
coaching can be used in stage III NSCLC patients is topic of ongoing research. If this 
seems applicable, the gating window can be prolonged, which would shorten the 
treatment time for each fraction. 
 
In stage III NSCLC, the current standard treatment consists of concurrent chemo-
radiotherapy, a combination that has shown superior local control and survival rates 
when compared to sequential chemotherapy and radiotherapy [23, 24]. However, an 
important limiting factor in the management of stage III NSCLC is treatment-related 
toxicity, such as radiation-induced pneumonitis. In addition, unexpected late toxicities 
have been reported in trials with radiation dose escalation after platinum based 
induction chemotherapy [25, 26]. One of the main causes of these toxicities is the 
relatively large volume that has to be treated in locally advanced lung cancer. Thus, in 
order to decrease the risk of radiation-induced toxicity, treatment volumes have to be 
reduced. Our analysis reveals that considerable volumetric and dosimetric gains can 
be achieved in most stage III lung cancer patients with the use of individualized PTVs. 
The additional gains that can be established with respiratory gating are generally 
modest, but correlate strongly with the reduction in mobility of the target volume. 
Since stage III lung tumors consist of a primary tumor and mediastinal lymph nodes, 
a reduction in mobility can be attributed to both these ‘individual’ structures. We also 
demonstrated that modest, but significant, dosimetric benefits can be obtained in 
tumors located in the middle and lower lobes. These two issues once again underscore 
the need for careful patient selection. Furthermore, our analysis shows a correlation 
between the reduction of toxicity parameters (V20 and MLD) and the PTV reduction 
achieved with respiratory gating, which can be used to identify benefits of gating in 
individual patients with stage III lung cancer. This correlation seems very obvious. 
However, we found this correlation to be valid for all GTV sizes which contradicts an 
earlier report that found dosimetric benefits for only GTVs smaller than 100-150 cm3 
[27]. 
 
SRT for stage I NSCLC requires careful monitoring of inter-fractional geometric 
changes of the target volume. These time-trends can arise due to changes in tumor 
volume, spatial position, or mobility during the course of radiotherapy. The former has 
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been described for several tumor sites, including locally advanced stage NSCLC [28] 
and head and neck cancer [29]. We observed an initial increase in GTVs and ITVs of 
>10 cm3 in only 5% of the stage I tumors treated with SRT, indicating that changes in 
tumor volume are not a very important reason for inter-fractional variations in target 
volumes during SRT for lung cancer. However, an important finding of our analysis is 
the incidence of inter-fractional positional shifts of ITVs during the 3-5 weeks course 
of SRT in a substantial portion of tumors. These shifts occur as early as one week 
after the start of SRT and may be caused by radiation-induced changes in the 
surrounding normal tissues, such as edema or retraction. Furthermore, we observed a 
change in 3D tumor mobility of >3 mm in 20% of tumors. It is of key importance that 
the interfraction changes in tumor position were not solely caused by changes in 
tumor mobility. This may be explained by the fact that 4DCT scanning was performed 
during uncoached quiet respiration in patients with generally poor pulmonary function, 
e.g. due to chronic obstructive pulmonary disease, which can cause variations in the 
respiratory signal at different 4DCT scans. These findings illustrate the importance of 
adequate treatment verification, e.g. by repeated imaging and adjustment of 
treatment plans during SRT for lung cancer in order to maintain adequate target 
coverage. This is performed for all patients treated with SRT in the VU University 
medical center for stage I NSCLC. Instead of repeated treatment planning, the 
geometric accuracy of the treatment can be verified prior to each fraction, which 
enables adjustment of the treatment portals. However, inter-fractional changes of the 
target consist of a spatial and a volumetric component, both of which have to be 
accounted for. For this purpose, measures have to be implemented for adequate 
imaging of the target volume, such as use of a cone beam CT scan that is installed at 
the treatment unit. For hypofractionated SRT an online verification protocol should be 
used in order to reduce both random and systematic errors and adjust treatment 
portals to the actual tumor position prior to each fraction. However, the clinical use of 
online verification requires additional treatment time. Furthermore, cone beam CT 
images should be reconstructed rapidly and should be of high quality. The main 
restrictions of cone beam CT imaging are the image acquisition time (usually 1 
minute), the reconstruction time and the image quality. Data collection is relatively 
slow due to the relatively slow gantry rotation. For lung tumors, this can result in 
respiration-induced artifacts, such as blurring and distortion, which can be compared 
to the images acquired from a slow CT scan. However, a recent report stated that 
image quality was sufficient for accurate discrimination of soft-tissue structures, and 
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that lung tumors were clearly visualized [30]. Two recent publications report on the 
reduction of respiration-induced artifacts in cone beam CT images by simultaneous 
recording of the patient’s respiratory cycle to obtain time-resolved images [31], and 
through incorporation of a patient’s motion model into the image reconstruction 
process [32]. 
 
Finally, our analysis confirms the finding of earlier reports that regression of lung 
tumors is a slow process, as significant decreases in target volumes have been 
observed after the fourth week of SRT [Chapter 5, this thesis]. Most tumor regression 
was, however, observed in the first three months after completion of SRT, which 
underscores the need for adequate follow-up. Another important reason for adequate 
follow-up is that this patient group is at risk for developing second primary lung 
tumors or regional recurrences, for which they can still undergo radical treatment with 
curative intent. 
 
Future directions to optimize 4D radiotherapy 
Several issues have to be established to optimize the clinical benefit of 4D 
radiotherapy. First, the reproducibility of respiratory motion during the patient’s 
breathing cycles has to be guaranteed. The amplitude and frequency of the 
respiratory signal can vary during free breathing. This may lead to systematic and/or 
random errors in the entire chain of treatment planning and execution. Therefore, 
further research on the reproducibility of respiratory waveforms and tumor position is 
necessary to facilitate the clinical use of gated radiotherapy. One method for 
improving reproducibility is respiratory coaching. However, it remains to be tested 
whether respiratory coaching is generally applicable in lung cancer patients, as many 
of these patients have cardio-pulmonary co-morbidity. Theoretically, respiratory 
coaching offers a potential clinical application for radiotherapy in lung cancer, 
particularly for SRT. Since this treatment is administered in a limited amount of 
fractions, one has to make sure that a change in the respiratory signal, compared to 
that during 4D image acquisition, does not lead to unnecessary tumor miss.  For this 
purpose predictive software is required at the treatment unit that adequately 
compares the respiratory signal during each fraction with that recorded during 4D 
image acquisition in an effort to obtain a more reproducible target volume. 
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It has been reported that respiration-induced motion can lead to significant changes in 
the dose distribution in normal organs, due to the fact that the doses to normal 
tissues are incorrectly displayed without including patient-related geometric 
uncertainties. [33]. However, it is presently not possible to fully explore the 
dosimetric benefits of 4DCT data, as current commercial treatment planning systems 
are not capable to incorporate 4DCT data in dose-calculation (time-weighted 
dosimetry), which is essential to adequately assess the risk of normal tissue toxicity. 
In addition, an adequate dosimetric analysis of a 4D treatment plan includes the total 
mobility of the target volume, as well as that of adjacent uninvolved organs. For this 
purpose, the ICRU Report 62 [3] recommends the use of planning organ at risk 
volumes (PRVs) in order to account for geometric uncertainty. However, generation of 
PRVs requires knowledge on organ mobility, which is not generally available. 
Furthermore, deformable registration, a software tool that relates 4DCT volumes of 
different respiratory phases to each other, is also not commercially available. This 
compromises the clinical use of 4DCT information, both for large tumors (e.g. stage 
III NSCLC) and normal organs at risk. 
 
Conclusions 
 This thesis deals with the clinical implementation of 4DCT scanning in radiotherapy 
practice for lung cancer. Several chapters highlight the fact that determination of 
individual margins should replace the use of ‘population based’ margins. Radiotherapy 
planning based on individual 4DCT data greatly reduces the risk of geometric errors in 
treatment delivery for both stage I and stage III NSCLC. In addition, it enables 
respiration-gated treatment delivery in order to achieve further PTV reduction. The 
incorporation of 4DCT data into lung cancer treatment planning has paved the way for 
the routine clinical use of image-guided radiotherapy. It ensures that complex 
radiation treatment can be delivered precisely. This may ultimately lead to improved 
tumor control and reduced treatment-related toxicity. 
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Summary 
 
In the Introduction to this thesis, an overview is provided about the current 
standard of external beam radiotherapy treatment planning and the use of population-
based margins for target definition. Although 3-dimensional conformal radiotherapy 
has been a major step forward in treatment planning for lung cancer, geometric errors 
can be introduced if tumor mobility is not taken into account. Several approached are 
discussed to deal with this problem. Furthermore, respiration-correlated (4D) CT 
scanning is introduced as a measure to incorporate respiration-induced tumor motion 
into target definition. This enables the use of individualized margins for mobility and, 
in addition, makes it possible to apply respiration-gated radiotherapy. 
 
The implementation of 4DCT scanning into clinical practice requires validation of this 
approach. This is provided in Chapter 2, in which the generation of an internal target 
volume (ITV) in stage I lung cancer patients using a single 4DCT scan was compared 
to that of six consecutive rapid ‘multislice’ CT scans and a single conventional CT scan 
to which standard margins were added. The results show that a single 4DCT scan 
generates comparable or larger ITVs than six rapid CT scans, thus improving target 
definition. Furthermore, the use of a single CT scan with a standard margin of 10 mm 
margin seemed inappropriate in some cases. 
 
The use of 4DCT scans in stage I lung cancer leads to an increased workload, as gross 
tumor volumes (GTVs) and/or normal organs have to be contoured in at least ten 
respiratory phases. To reduce the workload, measures have to be implemented for 
quick ITV generation. Chapter 3 illustrates that maximum intensity projections 
(MIPs) are a reliable post-processing tool for generating ITVs from 4DCT datasets. In 
addition, MIPs can be used for a rapid assessment of tumor mobility. 
 
The clinical toxicity of hypofractionated stereotactic radiotherapy (SRT) for stage I 
non-small cell lung cancer (NSCLC) is limited. However, as dose fractions of up to 20 
Gy are used, a reduction in size of treatment portals reduces the risk of toxicity to 
adjacent structures. In Chapter 4 a retrospective analysis is presented, which shows 
that respiration gated SRT enables a significant reduction to be achieved in normal 
tissue volume receiving the prescribed dose. In addition, a rapid assessment for 
Summary 
 
108 
identification of patients that derive significant benefit from this approach is reported. 
Although planning target volumes can be reduced by over 50% with respiratory 
gating, compared to the use of standard margins, only 15% of the patients in this 
analysis qualify for this criterion. 
 
Chapter 5 highlights the inter-fractional changes of the target volume that can occur 
during a course of SRT for stage I NSCLC. These have both a volumetric and a 
positional component. A significant decrease of the target volume was observed at the 
fourth week of treatment. On the contrary, inter-fractional positional shifts in the ITV 
of more than 5 mm were seen in up to 43% of patients, stressing the need to account 
for these possible time trends during the treatment course, e.g. by repeat CT planning 
or adequate on-board verification of the target volume. 
 
Patients with lung cancer who present with stage I disease are in a minority, and most 
patients who are treated with high-dose radiotherapy have locally advanced, stage III 
disease. Concurrent chemo-radiotherapy has shown superior local control and survival 
rates for stage III NSCLC compared to sequential chemo-radiotherapy or radiation 
alone. However, concurrent chemo-radiotherapy has also substantially increased the 
incidence of treatment-related toxicity. As respiration-gated radiotherapy allows for a 
reduction in target volumes, the benefits of this approach were explored in Chapter 
6, as well as incorporation of all respiration-induced motion into treatment planning. 
This analysis once again highlights the inappropriateness of population-based margins 
that are added to a GTV based on a single planning CT scan. Furthermore, it was 
observed that modest, but significant, dosimetric benefits (in V20 and mean lung dose) 
could be achieved, particularly for tumors located in the middle and lower lobes.
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In de Introductie van dit proefschrift wordt een overzicht gegeven betreffende de 
huidige klinische standaard van het planningsproces voor uitwendige bestralingen en 
het toevoegen van standaard marges om tot een uiteindelijk doelvolume te komen. 
Hoewel het uitvoeren van 3-dimensionale bestralingstechnieken een enorme stap 
voorwaarts is geweest voor bestralingsplanningen bij longkanker, kunnen 
geometrische onnauwkeurigheden worden geïntroduceerd wanneer geen rekening 
gehouden wordt met tumorbeweeglijkheid. Om dit klinische probleem op te lossen 
worden verschillende methoden belicht. Hiernaast wordt een korte beschrijving 
gegeven over ademhalings-gecorreleerde (4D) CT scans, welke het mogelijk maken 
om ademhalings-gerelateerde tumorbeweeglijkheid te incorporeren in de bepaling van 
het uiteindelijke doelvolume van de bestraling. Tevens verschaffen 4DCT scans de 
mogelijkheid om tijdens de behandeling de bestraling alleen toe te dienen tijdens een 
bepaald deel van de ademhalingscyclus (‘gate’), welke vooraf bepaald wordt. Deze 
bestralingstoepassing wordt ‘respiratory gating’ genoemd. 
  
De klinische implementatie van 4DCT scans vereist validatie van deze methode ten 
opzichte van de tot dan toe gebruikte klinische standaard. Dit wordt uiteen gezet in 
Hoofdstuk 2, waarin het ‘internal target volume’ (ITV; het volume dat alle posities 
van een tumor met zijn microscopische uitbreiding omvat), dat is gebaseerd op een 
enkele 4DCT scan, wordt vergeleken met dat zes conventionele, multislice CT scans 
en dat gebaseerd op een enkele conventionele CT scan na toevoeging van een 
standaard marge. De resultaten tonen dat een enkele 4DCT scan vergelijkbare of 
grotere ITVs oplevert in vergelijking met zes conventionele plannings-CT scans, 
waardoor het doelvolume nauwkeuriger kan worden gedefinieerd. Hiernaast blijkt dat 
zelfs het toevoegen van een standaard marge van 10 mm aan een ingetekend 
tumorvolume op basis van een enkele conventionele CT scan tot veel grotere 
doelvolumes leidt, die in sommige gevallen echter nog onvoldoende zijn. 
 
De toepassing van 4DCT bij het stadium I niet-kleincellig longcarcinoom heeft geleid 
tot een aanzienlijke toename van de klinische werkdruk, daar het ‘gross tumor 
volume’ (al het aantoonbare tumorweefsel) en/of de normale omliggende organen 
ingetekend moet worden op tenminste tien fasen van de ademhalingscyclus. Hiertoe 
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moeten maatregelen worden getroffen om op een zo efficiënt mogelijke wijze een ITV 
te verkrijgen. In Hoofdstuk 3 wordt geïllustreerd dat het gebruik van ‘maximum 
intensity projections’ (MIPs; een reconstructietechniek gebaseerd op CT informatie 
waarbij van elke pixel alleen de hoogste dichtheid wordt weergegeven) een 
betrouwbare methode vormen voor het genereren van ITVs uit alle 4DCT informatie. 
Ook wordt beschreven dat MIPs kunnen worden toegepast om op een snelle manier 
tumorbeweeglijkheid in kaart te brengen. 
 
De klinische toxiciteit van gehypofractioneerde stereotactische radiotherapie voor het 
stadium I niet-kleincellig longcarcinoom is beperkt. Echter, omdat er per fractie doses 
tot 20 Gray worden toegediend, wordt de kans op toxiciteit verder verlaagd door de 
bestralingsvelden te verkleinen. In Hoofdstuk 4 wordt een retrospectieve analyse 
beschreven, welke laat zien dat het toedienen van stereotactische bestraling tijdens 
een vooraf gedefinieerd deel van de ademhaling het mogelijk maakt om het volume 
aan normaal weefsel dat de totale dosis ontvangt, significant te reduceren. Tevens 
wordt een methode gepresenteerd waarmee op snelle wijze patiënten kunnen worden 
geselecteerd die het meeste voordeel zullen hebben van deze bestralingstoepassing. 
Uit de analyse blijkt verder dat hoewel met ‘gating’ doelvolumina met meer dan 50% 
kunnen worden gereduceerd in vergelijking met het gebruik van standaard marges, 
slechts 15% van de patiënten aan dit criterium voldoet. 
 
In Hoofdstuk 5 worden enkele belangrijke veranderingen gerapporteerd, die kunnen 
optreden tussen de verschillende sessies van een complete behandeling 
stereotactische radiotherapie voor het stadium I niet-kleincellig longcarcinoom. Deze 
bestaan uit zowel een verandering in grootte, als een verandering in positie van het 
doelvolume. Er werd een significante afname in grootte van het doelvolume 
waargenomen in de vierde week van de behandeling. Verandering in de positie van 
het doelvolume van meer dan 5 mm werden waargenomen bij tot wel 43% van de 
patiënten. Dit onderschrijft het belang om tijdens de behandeling rekening te houden 
met dergelijke trends. Dit kan bijvoorbeeld geschieden door het herhalen van de 
gehele planningsprocedure waarbij gebruik wordt gemaakt van een nieuwe plannings-
CT scan of door middel van adequate verificatie van het doelvolume op het 
bestralingstoestel. 
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Bij een minderheid van de patiënten met niet-kleincellig longcarcinoom wordt de 
ziekte in een vroeg stadium (stadium I) gediagnostiseerd. De meeste patiënten die 
worden behandeld met hooggedoseerde radiotherapie, hebben de ziekte in een verder 
gevorderd stadium (stadium III). Van gelijktijdige behandeling met chemotherapie en 
radiotherapie bij het stadium III niet-kleincellig longcarcinoom is aangetoond dat dit 
een hogere locale tumorcontrole geeft en de overleving van deze patiëntengroep 
verbetert, in vergelijking met sequentiële behandeling met deze twee modaliteiten. 
Daar staat echter tegenover dat gelijktijdige toepassing van deze behandelingen 
aanzienlijk meer toxiciteit veroorzaakt. In Hoofdstuk 6 wordt beschreven wat het 
dosimetrische voordeel is wanneer ‘respiratory gating’ wordt toegepast bij dit type 
tumoren, gezien het feit dat deze manier van bestralen het mogelijk maakt om 
kleinere doelvolumes te behandelen. De analyse die in dit hoofdstuk is uitgevoerd, 
toonde opnieuw aan dat het gebruik van standaard marges veel onnauwkeurigheid 
met zich meebrengt. Daarnaast werd aangetoond dat relatief geringe, doch wel 
statistisch significante, dosimetrische (zowel in V20 als in de gemiddelde longdosis) 
verbeteringen konden worden bereikt met het toepassen van ‘respiratory gating’. Dit 
gold in het bijzonder voor tumoren welke gelokaliseerd waren in de midden- en 
onderkwab. 
  
 
Dankwoord 
 
113 
Dankwoord 
 
Een proefschrift schrijven kun je niet alleen. Ik wil hier dan ook iedereen bedanken die 
ook maar enigszins heeft bijgedragen aan de totstandkoming hiervan met een extra 
paar handen, extra ideeën of simpelweg wat afleiding. Een aantal van hen wil ik in het 
bijzonder bedanken voor hun inzet en bijdrage. Gedurende mijn onderzoeksperiode op 
de afdeling radiotherapie van het VUMC hebben meerdere mensen, direct of indirect, 
hun medewerking verleend. Het is dus niet ondenkbaar dat ik iemand vergeet en bij 
voorbaat wil ik hiervoor mijn excuses aanbieden. 
 
Allereerst wil ik mijn beide promotoren, prof. dr. S. Senan en prof. dr. B.J. Slotman 
bedanken. Beste Suresh, jouw interesse voor de snelle implementatie van 4DCT 
scanning in de kliniek heeft ervoor gezorgd, dat ik in hoog tempo dit promotie 
onderzoek kon uitvoeren. Dit was mede mogelijk door jouw scherp inzicht en sturing 
die je aan het onderzoek gegeven hebt. Tevens ben ik ontzettend onder de indruk 
geraakt van de onvoorstelbare database aan literatuur, die in jouw hoofd zit. Het zal 
een grote (en waarschijnlijk onmogelijke) uitdaging zijn voor mij om dit te evenaren. 
Ook wil ik mijn dank uitspreken voor je flexibele houding ten opzichte van mijn 
werktijden tijdens de voorbereidingen van mijn huwelijk met Ashra.  
Beste Ben, jij hebt mij de mogelijkheid geboden om te werken op de afdeling 
radiotherapie van het VUMC en een groot deel van mijn AGNIO periode te wijden aan 
wetenschappelijk onderzoek. Als opleider en hoofd van de afdeling, en alle 
nevenactiviteiten die daarbij horen, ben je daarbij meer op de achtergrond betrokken 
geweest. Desalniettemin heb ik altijd veel gehad aan je snelle en kritische 
commentaar. Heel veel dank daarvoor en ik hoop ook de rest van mijn opleiding met 
veel plezier en wijsheid af te ronden. 
 
Verder ben ik zeer veel dank verschuldigd aan mijn co-promotor dr. F.J. Lagerwaard. 
Beste Frank, het is voor een heel groot deel aan jou te danken dat dit ‘4D’ proefschrift 
er ligt. Onder jouw kundige begeleiding zijn de meeste artikelen geschreven en samen 
met jou heb ik heel wat data vergaard in de afgelopen jaren. Dankzij de vele 
discussies en jouw zeer concrete inbreng zijn mijn wetenschappelijke schrijfstijl en 
denkpatroon enorm vooruit gegaan. Jouw promotie gedurende mijn 
onderzoeksperiode was voor mij een inspiratiebron om hetzelfde te bewerkstelligen. 
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De vele uren die we op de ‘F’ hebben doorgebracht, hebben dan ook zeker hun 
vruchten (en conditie) afgeworpen! Wellicht dat hier in de toekomst weer wat tijd voor 
is. 
 
Daarnaast was er ook de zeer aangename en intensieve samenwerking met dr. J.R. 
van Sörnsen de Koste. Beste John, jij hebt mij getoond wat er allemaal mogelijk is 
met ruwe data. In een handomdraai toverde jij de mooiste figuren tevoorschijn voor 
artikelen, posters en powerpoint presentaties. Dankzij jou heb ik geleerd dat er in de 
wetenschap meerdere wegen naar Rome leiden en dat het niet erg is om halverwege 
een ingeslagen weg om te draaien en een andere te kiezen. Ook jouw promotie heeft 
mij uiteraard gemotiveerd om mijn onderzoeksperiode hiermee te bezegelen. Tevens 
heb je me veel tips gegeven die het maken van de lay-out van dit proefschrift hebben 
vergemakkelijkt. Heel hartelijk dank hiervoor. 
 
Ik dank alle co-auteurs voor hun hulp en commentaar en natuurlijk ook al mijn 
collega’s van de afdeling radiotherapie van het VUMC voor de getoonde belangstelling 
voor de voortgang van mijn onderzoek. Ik hoop ook in de toekomst nog heel prettig 
met jullie samen te werken. 
 
Ik wil alle leden van de leescommissie danken voor het doorlezen en beoordelen van 
dit proefschrift. 
 
Verder dank ik alvast mijn paranimfen, Ralph Mebus en Jan Underberg voor de morele 
steun tijdens mijn verdediging. 
 
Mijn ouders wil ik heel erg bedanken voor alle mogelijkheden en steun die ze me 
hebben gegeven tijdens mijn studie en loopbaan tot nu toe. Heel veel dank voor deze 
uitstekende start. Jullie stonden, staan nog steeds, en zullen altijd voor mij klaarstaan 
als ik jullie nodig heb, ook wanneer ik het zelf niet besef. Ik kan alleen maar hopen 
dat ik zelf ook zo’n goede ouder zal zijn! 
 
Tenslotte grote dank aan de allerbelangrijkste persoon in mijn leven. Lieve Ash, 
getrouwd met jou door het leven gaan, is de beste keus die ik ooit gemaakt heb. Jouw 
geduld, steun en begrip zijn werkelijk grenzeloos, getuige alle keren dat ik ’s avonds 
achter de computer verdween. Dank je voor het feit dat je mij met veel praten door 
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een moeilijke periode hebt gesleept. Met elkaar gaan wij de toekomst met veel plezier 
tegemoet. Laten we beginnen met een lange vakantie. Wat dacht je van……Nieuw-
Zeeland? 
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René Widjai Marcel Underberg werd geboren op 7 april 1978 te Gainesville, Florida, 
USA. Na zijn basisschool periode (‘De Beiaard’ in Utrecht) en het afronden van het 
Gymnasium aan het College Blaucapel te Utrecht, startte hij in 1996 zijn opleiding 
geneeskunde aan de Vrije Universiteit te Amsterdam. Tijdens het keuzevak oncologie 
had hij zijn eerste ontmoeting met de radiotherapie in de vorm van een 
introductiecollege (door prof. dr. Slotman). In november 2002 werd het artsexamen 
behaald en kort hierop (januari 2003) startte hij zijn werkzaamheden als AGNIO op de 
afdeling radiotherapie van het VU medisch centrum te Amsterdam. Na een klinische 
periode van 10 maanden ving hij zijn promotie onderzoek aan in oktober 2003. Daar 
de afdeling radiotherapie kort daarna een eigen CT scanner kreeg met de mogelijkheid 
tot het vervaardigen van 4DCT scans, was de richting van het onderzoek al snel 
bepaald en het onderzoek verliep dan ook in hoog tempo. Zijn fulltime 
onderzoeksperiode eindigde op 1 maart 2005, waarna hij een half jaar stage liep op 
de afdeling interne-oncologie van het Zaans Medisch Centrum te Zaandam. Inmiddels 
is hij gestart met zijn opleiding tot radiotherapeut-oncoloog. 
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